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Chronic kidney disease 
Chronic kidney disease (CKD) is a public health problem that affects 10-16% 
of the global adult population1. Consequently, an important part of the health care 
resources are designated to the treatment of CKD, and particularly to the treatment of 
end-stage renal disease (ESRD)2. Although therapies aiming to retard progression of 
CKD have been improved over the years no important advances have been made 
over the last 15 years. The most relevant improvements concern pharmacological 
blockage of the renin-angiotensin-aldosterone system (RAAS). Nevertheless, CKD 
remains progressive in many cases and CKD patients are still prone to development 
of cardiovascular disease, particularly when compared to the general population3. 
Cardiovascular disease is by far the leading cause of morbidity and mortality in 
dialysis patients and is the most important cause of hospitalization and death in 
CKD1-2. Considering the fact that many CKD patients progress to ESRD, and that the 
optimal treatment for ESRD is kidney transplantation, additional and better therapies 
that target progression of CKD and long-term outcomes after kidney transplantation 
are required.  
 
History of kidney transplantation 
 The first successful kidney transplantation was performed in 1954, when 
Ronald Herrick donated a kidney to his genetically identical twin brother Richard4. 
Inspired by this remarkable success, in 1959, cyclophosphamide was used for the 
first time as an immunosuppressive drug. In the early 1960s, the first 
immunosupressive treatment became a clinical reality allowing the development of 
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renal transplantation as an established mode of renal replacement therapy5. Anno 
2015, advanced multi-drug immunosuppressive regimens have been developed, 
allowing a more individually tailored approach with greatly improved graft and patient 
survival as compared to the early days. This approach aims at minimizing the risk of 
acute rejection and drug-induced nephrotoxicity along with avoidance of too strong 
immunosuppression predisposing to, among others, infectious complications. As a 
result, kidney transplantation has become the treatment of choice for ESRD.  
 
Outcome after kidney transplantation 
Both graft and patient survival have increased steadily over the past decades 
as a result of improvements in surgical techniques, immunosuppressive regimens, 
and prophylaxis against opportunistic infections6. However, no relevant progress was 
made in prevention of chronic allograft failure and late cardiovascular morbidity and 
mortality. As a consequence, death and morbidity due to cardiovascular disease and 
late graft failure caused by chronic allograft nephropathy have surpassed infection 
and early allograft failure due to acute rejection as the primary threats to renal 
transplant recipients7. Cardiovascular disease is the primary cause of death in renal 
transplant recipients, responsible for 30% to 50% of total mortality8. Blood pressure, 
cholesterol levels and diabetes mellitus are classical cardiovascular risk factors that 
occur commonly after renal transplantation. Therefore it is recommended that these 
factors are monitored and treated in order to reduce cardiovascular complications9. 
However, in the renal transplant population, non-classical risk factors are very likely 
to also contribute to the cardiovascular risk. One of these non-classical risk factors is 
vascular calcification, which even can occur after successful kidney transplantation 
10 
 
and predisposis to premature (cardiovascular) mortality in this population10-11. It is still 
not fully elucidated why some patients demonstrate rapid progression of vascular 
calcification, while other patients remain free of calcifications for many years12-13. 
Calcification propensity depends on the balance between promotors (including  
serum calcium and serum phosphate) and inhibitors (including fetuin A, magnesium, 
vitamin K and pyrophosphate) of calcification. It remains unclear whether modulation 
of these factors could influence prognosis of CKD patients and/or renal transplant 
recipients14. 
 
Deregulated mineral metabolism and cardiovascular disease 
Deregulations in calcium/phosphate homeostasis (hyperphosphatemia, 
hyperparathyroidism, vitamin D deficiency) are independently associated with an 
increased risk of cardiovascular disease and mortality in patients with and without 
CKD. These findings have recently been extended by the discovery of the 
phosphaturic hormone fibroblast growth factor 23 (FGF23)15. 
In patients with chronic kidney disease (CKD), phosphate homeostasis is 
presumably disturbed in the first place due to an impaired renal capacity to excrete 
phosphate. FGF23 levels increase in parallel with renal function decline from an 
estimated GFR of approximately 60 ml/min/1.73 m2 and on (Figure 1)15. The main 
function of the rise in FGF23 seems induction of phosphaturia in order to normalize 
serum phosphate levels. Elevated levels of FGF23 have been associated with an 
increased risk of mortality and left ventricular hypertrophy in hemodialysis patients 
and progression of chronic kidney disease and atherosclerosis in CKD16-19.  
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Recently, high levels of FGF23 have also been linked to transplant failure and 
mortality in renal transplant recipients. This increased risk was independent of known 
risk factors20.  
Taken together with experimental data, these findings suggest that FGF23 
plays a pathophysiological role in the increased cardiovascular risk associated with 
deranged mineral metabolism. The mechanisms underlying the adverse actions of 
FGF23 are only partially understood.  A high FGF23 level, albeit required to reduce 
serum phosphate level in the context of impaired renal function, also has off-target 
effects directly promoting left ventricular hypertrophy21. Furthermore, interaction 
between FGF23 and the renin-angiotensin-aldosterone system (RAAS) may 
contribute to the adverse cardiorenal outcomes associated with high FGF23 22. 
Figure 1 
 
Figure 1. Prevalence of hyperphosphatemia, secondary hyperparathyroidism and elevated 
FGF23 in relation to eGFR. Hyperphosphatemia was defined as serum phosphate ≥ 4.6 mg/dl, 
secondary hyperparathyroidism as PTH ≥ 65 pg/ml and FGF23 excess as FGF23 ≥ 100 RU/ml.. 




The interaction between FGF 23 and the RAAS is probably mediated by 
effects which operate through other regulators of mineral metabolism, i.e. vitamin D 
and klotho. High FGF23 levels reduce the activity of the enzyme 1-hydroxylase, 
leading to reduced production of active vitamin D (1,25(OH)2 vitamin D). Low levels of 
active vitamin D increase activity of the renin-angiotensin-aldosterone system 
(RAAS)22, resulting in high levels of angiotensin II. Angiotensin II suppresses renal 
expression of klotho,22 which is a transmembrane protein that forms a complex with 
fibroblast growth factor (FGF) receptors and functions as an obligate co-receptor for 
FGF23. Thus, renal loss of klotho expression in turn results in elevated circulating 
levels of FGF2322-23. By these interactions, there is a vicious circle consisting of high 
FGF23 levels, low vitamin D levels, RAAS activation, and renal klotho loss in CKD 
patients (Figure 2). Additionally, other factors such as renal inflammation induce a 





Figure 2. Cross talk between vitamin D (red), FGF-23-Klotho (yellow), and the RAAS (blue) in healthy 
subjects and patients with chronic kidney disease. In the normal situation (left panel), active vitamin D 
(1,25(OH)2 vitamin D), generated by renal 1-alpha hydroxylase, suppresses renal renin production. 
When the RAAS is not activated (low angiotensin II), renal klotho levels are sufficient to allow normal 
function of the FGF-23 receptor. Therefore, levels of FGF-23, a negative regulator of 1-alpha 
hydroxylase, are normal under these conditions. In chronic kidney disease (right panel), the RAAS, 
vitamin D, FGF-23 and klotho are concertedly disturbed. (1) Activity of 1_-hydroxylase is reduced due 
to nephron loss and high FGF-23 in CKD, leading to (2) reduced production of 1,25(OH)2-vitamin D, 
which in turn upregulates renal renin production. (3) The subsequent higher levels of angiotensin II 
cause renal klotho loss and (4) disrupted FGF-23 signaling, impairing phosphaturia and rising FGF-23 
levels. RAAS activation, vitamin D deficiency, high FGF-23 levels and low renal klotho have all been 




As the evidence for a pathogenic role of high FGF23 levels becomes more 
clear, it is crucial to identify its determinants. The two major determinants of FGF23 
known to date are renal function and diet. Since the main function of FGF23 is to 
induce phosphaturia in response to a high dietary phosphate load, a straightforward 
approach targeting FGF23 would be to lower phosphate intake. This particularly 
applies to patients with impaired renal function. A recent study suggested that mainly 
animal proteins are a major source of phosphate, impacting on FGF23 levels25, so 
that reduction of animal protein might be useful. Whether other dietary factors also 
influence FGF23 has been unclear so far, yet this is an important field to be explored. 
 
Dietary factors and outcomes in renal patients  
CKD 
An optimal diet is crucial for a CKD patient’s health status, but difficult to 
achieve. Dietary requirements evolve over the course of the renal condition, and, in 
patients with ESRD, also depend on the mode of renal replacement therapy. In early 
CKD, dietary recommendations are more or less similar to those for other 
cardiovascular high risk groups, namely: use a healthy diet and avoidance of 
excessive sodium intake. Sodium restriction potentiates the antiproteinuric efficacy of 
RAAS blockade and is required to allow for the renal and cardiovascular protective 
effects of RAAS blockade to occur. A modest reduction of dietary sodium intake to 2 
g/day is associated with a 30% reduction of urinary protein excretion and combining it 
with RAAS blockade synergistically reduces proteinuria in non-diabetic CKD 
patients26-27. In contrast, high sodium intake has been reported to blunt the 
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antiproteinuric effect of ACE inhibitor therapy and increase the risk for ESRD and its 
complications28. Dietary protein restriction is considered useful in patients with overt 
proteinuria29-30. 
When renal function loss progresses, dietary restrictions get more extensive, 
and are required to keep fluid status and blood pressure, serum urea, phosphorus, 
potassium and bicarbonate levels within range. This may, however, result in a severe 
limitation of food choices and less tasteful meals, thereby compromising the patient`s 
adherence to the treatment31 or placing the patient at risk for inadequate intake of 
energy and protein, promoting the tendency for occurrence of malnutrition. In patients 
with CKD, accumulation of uraemic metabolites, metabolic acidosis, inflammation 
and other complicating factors contribute to decreased appetite, increasing the 
tendency for insufficient intake of energy and protein, leading to an even higher risk 
of  malnutrition32, making this a very common observation in patients with end-stage 
renal failure and in patients on dialysis. 
Dialysis patients with lower serum albumin levels, lower body mass and 
malnutrition are at higher risk of cardiovascular mortality33-35 demonstrating the major 
role of adequate nutritional status in these patients. In these patiens, like in patients 
with end-stage renal failure, the trade-off is between adequate protein intake and the 
adverse effects of the (usual) concomitant rise in intake of phosphate, acid load, and 
the increase in uremic waste products.  
Dietary interventions reporting long term outcomes in CKD are even more 
scarce than in the general population. The abovementioned data on effect of 
moderate sodium restriction were obtained from post-hoc analyses in prospective 
pharmacological intervention trials. Yet, they are well in line with those of the 
prospective sodium intervention in the TOPH trials, that demonstrated that 
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sodium restriction reduces blood pressure and may also reduce the long-term risk 
of cardiovascular events36. Of the few large dietary interventions trials that have been 
performed, the beneficial effects observed for the Mediterranean diet stand out as 
highly promising. The Meditteranean diet is characterized by high intake of olive oil, 
fruit, nuts, vegetables and cereals, moderate fish and poultry intake and lower 
consumption of dairy foods, red and processed meats and sweets, and prevents 
cardiovascular events in healthy subjects. Etruch et al 37 have shown that 0.1g/day of 
dietary N-3 PUFAs consumed through either olive oil or nuts prevented myocardial 
infarction 37 . 
Patients with ESRD have a lower ratio of N-3 to N-6  PUFAs levels , which 
independently predicts accelerated cardiovascular disease38, and N-3 PUFAs have 
been associated with a lower risk of myocardial infarction as a secondary outcome in 
CKD patients39. Accordingly, it would be of interest to assess whether the beneficial 
effects of N-3 PUFAs such as eicosapentaenoic (EPA) and docosahexaenoic (DHA) 
acids as reported in different disease conditions40, could also apply to CKD patients.  
 
Kidney transplantation 
For renal transplantation, data on dietary factors as determinants of outcome, 
and as target for dietary intervention are even more scarce than in CKD.  
For the classical cardiovascular risk factors such as hypertension and 
dyslipidemia, dietary recommendations are in line with those for other high risk 
groups30. However, our own group has recently shown that dietary intake in 
transplant recipients is not optimal, and does not meet recommendations for a 
healthy diet41, suggesting that clinical benefit could be obtained by more focus on 
meeting current dietary guidelines for a healthy diet.   
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Specific dietary factors such as protein intake, and protein source may also 
play a role in outcomes after kidney transplantation. A recent study has demonstrated 
that lower total protein intake is inversely associated with higher risk of mortality and 
graft failure in a renal transplant recipients population42. However, the authors did not 
provide information regarding the amount of plant and animal protein intake. 
Moreover, the mean intake of protein observed in that study was close to normal 
recommendations and not sufficiently high to allow assumptions on the potential 
effects of high protein intake on outcomes after kidney transplantation.  
Although it is largely unknown whether specific dietary interventions could be 
useful after renal transplantation, encourageing data from the 1990’s suggest that 
N3-PUFAs might be of benefit as supplementation of N-3 PUFAs early after 
transplantation was associated with fewer rejection episodes, albeit no  translation 
into improvement in graft survival at one year after transplantation was observed43. 
Further, a meta-analysis addressing the effects of fish oil in renal transplants 
recipients reported improvements in lipid profile and blood pressure in patients who 
received fish oil supplementation for longer that six months. Unfortunately, benefits 
on cardiovascular outcomes could not be demonstrated44. Anti-inflammatory dietary 
factors, such as N-3 PUFAs, could exert beneficial effects on renal and 
cardiovascular outcomes by direct anti-inflammatory effects or indirect through 
interaction with phosphate homeostasis, as low-grade inflammation has recently 
been linked with deregulated phosphate metabolism45-46.  
Taken together, dietary factors could importantly contribute to optimization of 
patient outcome in CKD and the post-transplant setting. Specifically, dietary factors 
targeting mineral metabolism, which is commonly deregulated in these patients, 
warrants renewed interest, based on the consistent association of derangement with 
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adverse outcomes and the new insights gained on the alleged role of FGF23 as a 
novel, independent contributor to adverse outcome in CKD and after renal 
transplantation. It would be of particular interest, if FGf23 would be a novel, 
independent target for intervention.    
 
 
Aim of the thesis 
 
The aim of this thesis is to investigate the role of deregulated phosphate metabolism 
and FGF23 in relation to adverse cardiovascular outcomes in CKD and after kidney 
transplantation. Moreover, we aimed to study novel strategies targeting deregulated 
mineral metabolism, as reflected by e.g. high circulating FGF23 levels, using a 
dietary approach, specifically n-3 PUFAs, eicosapentaenoic (EPA) and 
docosahexaenoic (DHA) acids, at an experimental level, in CKD and transplant 
patients.  
 
Outline of the thesis 
In chapter 2, we review the consequences of disturbed phosphate 
metabolism on the cardiovascular system, kidney and bone, in renal transplant 
recipients. We focus on the early and late deregulations in phosphate metabolism, 
and address its clinical impact in both stages. Furthermore, we summarize current 
data on dietary and pharmacological strategies to improve phosphate metabolism in 
CKD, with a key focus on data in renal transplant recipients. In chapter 3, we 
investigate the association of circulating levels of FGF23 with cardiovascular and all-
cause mortality in renal transplant recipients, in the context of other markers of 
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mineral metabolism and cardiovascular risk factors. In chapter 4 we investigate the 
potential relationship of intake of fish and dietary determinants, as EPA-DHA, with 
serum FGF23 levels, in a well-defined cohort of 619 renal transplant recipients. 
Subsequently, in chapter 5, we investigate the effect of fish oil supplementation on 
renal expression of klotho, an essential co-factor for the FGF23 receptor, as well as 
renal inflammation and fibrosis, in a mouse model of inflammatory renal disease. 
Finally, in chapter 6, we address whether intervention with dietary n-3 fatty acid 
supplementation during 40 months could reduce plasma FGF23 levels in post-
myocardial infarction patients with impaired renal function (eGFR <60 ml/min/1.73 
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In chronic kidney disease, deregulations in phosphate metabolism including a high 
fibroblast growth factor 23 (FGF23) level, hyperparathyroidism and 
hyperphosphatemia are common. High levels of phosphate and FGF23 have been 
associated with an increased risk of cardiovascular morbidity and mortality in chronic 
kidney disease patients. Kidney transplantation elicits specific changes in phosphate 
metabolism, evolving over time and ranging from deep hypophosphatemia to 
hyperphosphatemia and high FGF23 levels. Early after transplantation, the majority 
of renal transplant recipients develop hypophosphatemia as a consequence of 
relatively slow adaptation of FGF23 and parathyroid hormone levels to restored renal 
function, and under the influence of immunosuppressive drugs. Later after 
transplantation, phosphate homeostasis is at least partially restored, paralleled by a 
substantially reduced cardiovascular risk compared with the pre-transplant setting. 
Yet in many renal transplant recipients abnormalities in phosphate homeostasis 
remain, often due to multifactorial causes, and may contribute to adverse outcomes 
on the cardiovascular system, kidney, and bone. Dietary and pharmacological 
interventions may improve phosphate homeostasis in renal transplant recipients; yet 
more insight in the pathophysiology of transplant-related abnormalities in phosphate 
homeostasis is needed to further optimize their management, aiming to improve the 





Chronic kidney disease (CKD) is accompanied by deregulations in phosphate 
metabolism. The first indication of disturbed phosphate metabolism is an increased 
fibroblast growth factor 23 (FGF23) level, which becomes apparent with an eGFR of 
<60 ml/min/1.73 m2. In more advanced stages of CKD, hyperparathyroidism and 
hyperphosphatemia develop. High levels of FGF23, hyperparathyroidism and 
hyperphosphatemia have all been associated with an increased risk of cardiovascular 
morbidity and mortality in the CKD population.  
Kidney transplantation is the preferred treatment for end-stage renal disease. 
Kidney transplantation induces specific changes in phosphate metabolism, ranging 
from deep hypophosphatemia associated with relatively high FGF and PTH levels 
early after transplantation, followed by normalization, and finally to the recurrence of 
high levels of FGF23, PTH and serum phosphate associated with renal function 
deterioration in the late post-transplant stage. These changes evolve over time in the 
transplanted patient and may contribute to cardiovascular complications, impaired 
graft function, and adverse skeletal effects. Here we will discuss the pathophysiology 
of deregulated phosphate metabolism in renal transplant recipients, and address its 
potential impact on the cardiovascular system, kidney and bone. We will also discuss 




Phosphorus is an important constituent of several cellular components 
including the phospholipid layer of the cell membrane, and it plays a role in key 
biological processes including energy metabolism. Only a fraction of the total body 
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phosphorus content is present in serum in the form of phosphate (PO43-). Yet serum 
phosphate is crucial for many processes in the body and, under healthy conditions, is 
tightly regulated between 0.8 and 1.5 mmol/l (2.5 and 4.5 mg/dL).  
The intestinal absorption of phosphate occurs via two different pathways: 
transcellular and paracellular routes (Figure 1a). Transcellular phosphate absorption 
in the intestine is mediated by the type IIb sodium–phosphate cotransporter (NaPi-
IIb), which is expressed on the luminal membrane of enterocytes in the ilium. The 
hormonal factors controlling transcellular phosphate transport have not been fully 
clarified, but NaPi-IIb is probably regulated by 1,25-dihydroxyvitamin D3 and dietary 
phosphate intake.1, 2 Phosphate is subsequently transported to the circulation on the 
basolateral side, through a not yet identified transporter or process. The paracellular 
pathway, which is diffusion-driven, is mostly regulated by dietary phosphate intake, 
and therefore intestinal phosphate absorption increases linearly according to the 
dietary phosphate intake.3 In the healthy kidney, phosphate is freely filtered by the 
glomerulus; approximately 80-90% of the phosphate filtered load is reabsorbed in the 
proximal tubular segment through type IIa (NaPi-IIa) and type IIc sodium–phosphate 




Figure 1. Molecular mechanisms of (a) intestinal phosphate absorption and (b) 
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In turn, NaPi-IIa is regulated by fibroblast growth factor 23 (FGF23), and both 
NaPi-IIa and NaPi-IIc are regulated by parathyroid hormone (PTH).4, 5 FGF23 
suppresses the expression of NaPi-IIa,6 whereas PTH reduces NaPi-IIa availability in 
the tubular brush border membrane by stimulating its internalization.7, 8 The net result 
of a reduced presence of NaPi-IIa/c transporters on the luminal membrane of 
proximal tubular epithelial cells is enhanced urinary phosphate excretion 
-hydroxylase, FGF23 
reduces the conversion of 25-hydroxyvitamin D3 into 1,25-dihydroxyvitamin D3, 
resulting in less intestinal phosphate absorption.9 Thus, in response to dietary 
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phosphate loading, increased FGF23 levels lead to increased renal phosphate 
excretion and reduced intestinal phosphate uptake. Through these mechanisms, 
healthy individuals are able to maintain serum phosphate levels within a relatively 
narrow range. Interestingly, it is unclear to date which factor actually senses 
phosphate in the intestinal lumen and subsequently stimulates FGF23 production in 
bone tissue by osteocytes and osteoblasts. Given the fact that changes in serum 
phosphate do not precede changes in FGF23, it is highly unlikely that serum 
phosphate itself is the factor inducing FGF23.10  
In patients with CKD, phosphate homeostasis is disturbed, presumably in the 
first place due to an impaired renal capacity to excrete phosphate. The concept of 
positive phosphate balance in CKD has however been challenged by phosphate 
balance studies,11, 12 suggesting the involvement of additional mechanisms. These 
may include a role for NaPi-IIb, which at least partly mediates CKD-induced 
hyperphosphatemia. 13 Furthermore, an increased circulating FGF23 level is one of 
the first signs of deregulated mineral metabolism in chronic kidney disease (CKD-
MBD). FGF23 levels increase in parallel with renal function decline from an estimated 
GFR of approximately 60 ml/min/1.73 m2.14 One of the consequences of a high 
FGF23 level is suppression of vitamin D activation in proximal tubular epithelial cells. 
In turn, lower 1,25-dihydroxyvitamin D3 levels stimulate the parathyroid glands to 
release increasing amounts of PTH: secondary hyperparathyroidism ensues.14, 15 The 
triad of hyperparathyroidism, a high FGF23 level and vitamin D deficiency aims at 
minimizing intestinal phosphate uptake while maximizing urinary phosphate 
excretion; however these changes also contribute to undesirable effects including 







Phosphate homeostasis after kidney transplantation 
Deregulated phosphate homeostasis in renal transplant recipients may result 
in either low or high serum phosphate levels, depending on the post-transplant stage 
as well as on renal function. When renal function is (partly) restored after successful 
kidney transplantation, massive phosphaturia may develop since FGF23 and PTH 
levels remain high for weeks to months post-transplantation (Figure 2).16-19  




Although circulating FGF23 and PTH levels decline after transplantation, 
FGF23 levels in renal transplant recipients are higher compared to CKD patients with 
the same renal function.20 PTH levels may remain high due to persistent secondary 
hyperparathyroidism with impaired graft function, or due to tertiary 
hyperparathyroidism. Furthermore, vitamin D deficiency is common in renal 
transplant recipients, and may contribute to persistently high PTH levels as well.21  
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Relatively high FGF23 and PTH levels, in the context of a transplanted kidney able to 
excrete large amounts of phosphate, induce phosphaturia (Figure 3).  
 




In addition, glucocorticosteroid treatment after transplantation may contribute 
to the development and maintenance of post-transplant hypophosphatemia, as 
observed in clinical studies.22 Experimental studies have shown that glucocorticoid 
treatment induces a decreased presence of Na-Pi cotransporter presence in the 
brush border membrane of tubular epithelial cells, resulting in less phosphate 
reabsorption.23, 24 Glucocorticoids also inhibit intestinal Na-Pi transporter activity.25 
Given the well-known toxic effects of calcineurin inhibitors to tubular epithelial cells, it 
is plausible to assume that these compounds could also contribute to the 
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development of post-transplant hypophosphatemia, although reported clinical cases 
are limited.26 In rats, cyclosporine inhibits Na-Pi cotransporter activity,27, 28 although 
this effect could not be demonstrated in humans.29 Rapamycin, an 
immunosuppressive compound selectively inhibiting mammalian target of rapamycin 
(mTOR), also influences renal phosphate handling30 and has been associated with 
hypophosphatemia in renal transplant recipients.31 Inhibitors of the mTOR pathway, 
including everolimus, also cause hypophosphatemia in non-renal populations.32, 33 
This occurs probably through an effect of mTOR inhibition on the expression of 
klotho, the co-factor for the FGF23 receptor, in tubular epithelial cells.34 Besides 
immunosuppressive medication, ischemia-reperfusion injury might also contribute to 
post-transplant hypophosphatemia, although the data to support this observation are 
limited.35 Finally, metabolic acidosis, which is relatively common after transplantation, 
also stimulates phosphaturia, since phosphate serves as a titratable acid.36 The 
aforementioned factors may all contribute to phosphaturia, which is compensated for 
by mobilization of phosphate from bone and enhanced intestinal absorption via 1,25-
dihydroxyvitamin D3. Yet in most patients this compensation is incomplete;37 
therefore, hypophosphatemia is a frequent finding in the early post-transplant period, 
occurring in up to 90% of renal transplant recipients within the first three months after 
transplantation.16, 38-41  
Later after successful kidney transplantation, when FGF23 and PTH levels 
have declined, serum phosphate levels return to the normal range. However despite 
normal serum calcium and phosphate levels, persisting abnormalities in FGF23, PTH 
and vitamin D may contribute to ongoing phosphate wasting.42 A recent cross-
sectional observational study found a significantly lower tubular reabsorption of 
phosphate normalized for glomerular filtration rate (TMP/GFR) in renal transplant 
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recipients with eGFR between 30 and 90 ml/min compared to their predialysis 
counterparts, matched for eGFR.43 This might mean that renal phosphate wasting 
persists in the late period of renal transplant even in patients with 
normophosphatemia.  
In contrast with post-transplant hypophosphatemia, which is most prominent in 
the early stage after kidney transplantation, renal function decline for example due to 
allograft rejection may cause levels of FGF23, PTH, and phosphate to (again) 
increase as in the pre-transplant CKD setting (Figure 4), which may have important 
implications for, among others, the cardiovascular system, kidney, and bone.  
 




Impact on the cardiovascular system 
In CKD patients, higher levels of both phosphate and FGF23 have been 
associated with an increased risk of cardiovascular disease and mortality (reviewed in 
44, 45). FGF23 and phosphate may have distinct yet related effects on the development 
or progression of cardiovascular disease. Increased inorganic phosphate uptake via Na-
dependent inorganic phosphate transporters is essential for in vitro calcification induced 
by a high-inorganic phosphate medium,46 in the same range as serum phosphate 
concentrations in hyperphosphatemic CKD patients.47 FGF23, on the other hand, had 
no effect on phosphate uptake or phosphate-induced calcification independent of 
phosphate concentration.48 Epidemiologic data suggest that in CKD, elevated FGF23 
levels are more closely linked to volume overload-related cardiovascular complications 
including left ventricular hypertrophy and heart failure, and to a lesser extent to ischemic 
heart disease.49 Indeed, translational studies support a potential causal role for FGF23 
in the development of left ventricular hypertrophy,50 and cardiac remodeling, in 
combination with klotho deficiency.51 This is in line with recent studies connecting 
FGF23 and renal sodium handling by the sodium-chloride cotransporter,52 and with a 
reduced antiproteinuric response to dietary sodium restriction.53  
Along with improved mineral metabolism, the cardiovascular risk of end-stage 
renal disease patients is drastically reduced after kidney transplantation. Yet, kidney 
transplant recipients remain at increased risk of cardiovascular morbidity and mortality 
when compared with the general population.54 Of note, vascular calcification progresses 
in many transplanted patients, even in those with stable renal function.55 The extent of 
vascular calcification predicts cardiovascular morbidity and mortality;56 therefore the 
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identification and treatment of the key forces driving residual calcification propensity is a 
major goal to improve outcomes after kidney transplantation. Until recently, the 
propensity to develop vascular calcification could not be quantified given its 
multifactorial nature. Furthermore, the interindividual variation in calcification propensity 
has been well recognized,57 but it is incompletely understood why some patients 
demonstrated rapid progression of vascular calcification and subsequently 
cardiovascular events, whereas another considerable group of patients remains free of 
calcifications for years.58, 59 A novel assay able to quantify calcification propensity in 
serum has recently been developed.60 In renal transplant recipients, calcification 
propensity was strongly associated with cardiovascular mortality, and serum phosphate 
was a major determinant of calcification propensity.61 This is well in line with 
epidemiological data indicating that in renal transplant recipients hyperphoshatemia is 
independently associated with an increased mortality risk, as in pre-transplant CKD.62  
High levels of FGF23 have also been associated with an increased risk of all-
cause mortality63 and cardiovascular mortality64 in renal transplant recipients. Although 
mechanistic studies addressing the cardiovascular effects of FGF23 in the transplant 
setting are lacking, clinical studies suggest that high FGF23 levels may contribute to an 
elevated cardiovascular risk in renal transplant recipients by an adverse effect on 
endothelial function.65 After transplantation, the decline in FGF23 level is paralleled by 
improved endothelial function in patients.66 Furthermore, FGF23 has consistently been 
associated with parameters of volume overload,64, 65 rather than classical 
atherosclerosis67, 68 in renal transplant recipients, in accordance with findings in the pre-




Impact on the kidney 
Whether deregulated phosphate metabolism contributes to progressive renal 
function loss has insufficiently been clarified. Although the potential nephrotoxic effect of 
enteric inorganic phosphate has been demonstrated in experimental studies,69, 70 no 
epidemiological studies have confirmed the link between dietary phosphate intake and 
chronic kidney disease (CKD) progression. Similarly, FGF23 has been associated with 
CKD progression,71, 72 but whether high FGF23 levels actually play a causal role in 
progression of renal function loss remains unclear. Yet, experimental studies suggest 
that intensive phosphate lowering73 as well as administration of klotho74-76 reduces renal 
inflammation and fibrosis in animal model of renal damage.  
After kidney transplantation, a higher serum phosphate level,77, 78 calcium-
phosphate product79 or FGF23 level63, 80 all have been independently associated with an 
increased risk of graft failure. These associations however do not conclusively imply a 
causal role for phosphate in the etiology of impaired graft function, as reverse causation 
as well as confounding by (subclinical) renal damage may play a role. Vitamin D 
deficiency, which may at least in part be due to high FGF23 levels, may however 
specifically impact graft outcome, given the effects of vitamin D on the immune 
system.81 Epidemiological studies indicate that vitamin D deficiency is associated with 
progression of interstitial fibrosis and a lower GFR one year after transplantation.82 A 
low level of 25-hydroxyvitamin D measured in a later stage (>1 year) after 
transplantation has also been linked with an accelerated eGFR decline in two studies in 
renal transplant recipients.83, 84  
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Impact on bone  
The loss of bone mass is a universal finding after kidney transplantation; lower 
bone mineral density (BMD) may be ascribed to type and dosage of 
immunosuppression, especially glucocorticoids, persistent or de novo CKD-mineral and 
bone disorder (CKD-MBD), and several other factors.85 It is recognized that post-
transplant hypophosphatemia may have a detrimental impact on bone mineralization.86, 
87 Post-transplant hypophosphatemia may be involved in impaired osteoblastogenesis 
and early osteoblast apoptosis further contributing to post-transplant osteoporosis. Bone 
biopsy data from renal transplant recipients performed between 22 and 160 days after 
kidney transplantation have shown that serum phosphate levels were lower in patients 
showing osteoblast apoptosis and correlated positively with osteoblast number and 
negatively with the number of apoptotic osteoblasts. Since a positive correlation 
between osteoblast surfaces and PTH levels was observed, it was suggested that PTH 
could exert a protective effect on bone by preserving osteoblast survival.86 On the other 
hand, in a model of adenine-induced uremia, NaPi-IIb-deficient mice had significantly 
lower levels of serum phosphate and attenuation of FGF23, compared with wild-type 
uremic mice. 13 Treatment with a phosphate binder (sevelamer) decreased the number 
of osteoclasts and the rate of mineral apposition in NaPi-IIb-deficient mice, but not in 
wildtype mice. This suggests that targeting NaPi-IIb in addition to phosphate binder 
therapy may be a therapeutic approach to modulate serum phosphate in CKD.  
In a retrospective observational cohort study,88 high FGF23 levels were associated with 
BMD loss at the lumbar spine and total hip region during the first post-transplant year, 
whereas low PTH levels were associated with BMD loss at all three regions. A recent 
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study extended these findings by demonstrating an association between persistent 
hyperphosphatemia after transplantation and an increased fracture risk.89 The clinical 
impact of FGF23 on bone changes after renal transplantation may at least in part be 
independent of hypophosphatemia, as suggested by experimental data obtained from 
FGF23 and NaPi-IIa null mice90 and by histomorphometric studies. 91 Moreover, 
adenoviral overexpression of FGF23 in fetal rat calvaria cells inhibited bone 
mineralization independent of systemic effects on phosphate homeostasis.92 Thus, the 
disturbed bone mineralization observed in renal transplant recipients may be partly the 
result of post-transplant hypophosphatemia but also partly of deregulated FGF23 
independently of serum phosphate. 
 
 
Strategies to improve phosphate homeostasis after kidney transplantation 
Summarizing the available data reviewed above, deregulations in phosphate 
metabolism are highly common after kidney transplantation. Either hypophosphatemia 
or hyperphosphatemia may develop, depending on several factors including the post-
transplant stage and renal function. The consistent associations of hyperphosphatemia 
and high FGF23 levels with adverse outcomes late after transplantation render 
optimization of phosphate metabolism as a potential treatment target to improve 
cardiorenal outcomes in renal transplant recipients. Several strategies have been 
investigated but evidence specific to the transplant population is limited. Therefore we 
will summarize available data from the CKD population as well, and discuss its 




The frequency by which serum phosphate and other mineral parameters require 
monitoring depends on several factors including the stage after transplantation, graft 
function, pre-existing mineral metabolism abnormalities, and (changes in) therapy likely 
to affect these parameters. During the immediate post-transplantation stage, KDIGO 
guidelines recommend to measure serum calcium and phosphate at least weekly, until 
stable.93 In a later stage after transplantation, when mineral metabolism has stabilized, 
the monitoring intervals may be prolonged in accordance with renal function, varying 
from every 6-12 months in patients with CKD stages 1-3T to every 1-3 months in stage 
5T.93 Determining the fractional excretion of phosphate, TmP-GFR, 1,25-
dihydroxyvitamin D and fibroblast growth factor 23 levels may be useful in selected 
patients. 
 
Phosphate supplementation  
The majority of patients with a functioning graft develop hypophosphatemia 
during the early post-transplant phase, which may require extensive supplementation. In 
our centre we generally use a serum phosphate level of 0.5 mmol/L as a lower cut-off to 
consider initiating supplementation therapy, since below this level clinical symptoms 
(mainly muscle weakness) may develop. Patients who complain of muscle weakness 
and have serum phosphate levels between 0.5-1.0 mmol/L may be supplemented to 
evaluate the clinical response. Supplementation can be accompanied by gastro-
intestinal side effects but, more importantly, it may also exacerbate an already existing 
secondary hyperparathyroidism and further enhance FGF23 levels.94 Although no 
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prospective studies of phosphate supplementation on graft outcomes are available, 
case reports suggest that supplementation might contribute to calcification of the native 
(nephrocalcinosis) or transplanted kidney.95, 96 Therefore, every attempt should be made 
in order to prescribe the strict minimum doses, and frequent follow-up remains indicated 
after initiation of supplementation, in order to monitor the effect and reduce the dose as 
soon as possible. Of interest, several observational studies have documented partial 
recovery of hypophosphatemia and a reduced supplementation requirement in patients 
treated with dipyramidole.97-99 Although the underlying mechanism is not entirely clear, it 
is probably related to the capacity of dipyramidole to lower adenosine uptake by tubular 
epithelial cells, preventing phosphate excretion induced by cyclic AMP and decreasing 
the phosphaturic effect of parathyroid hormone.100  
 
Dietary interventions to reduce phosphate 
In the setting of impaired graft function, secondary hyperparathyroidism, higher 
FGF23 levels, and ultimately hyperphosphatemia can recur, and may require dietary as 
well as pharmacological interventions.101 Sources of dietary phosphate include products 
rich in animal proteins such as meat and dairy, providing organic phosphate, and food 
preservatives found in instant products, fast foods, snacks, cheese and soft drinks, 
particularly cola, providing inorganic phosphate.102 Only 30-60% of organic phosphate is 
absorbed in the intestinal tract, as opposed to over 90% of inorganic dietary phosphate. 
The increased use of phosphate additives coupled with the increased popularity of 
convenience foods has led to an increased dietary phosphorus load in Western and 
developing countries over the past decades.102 
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Dietary phosphorus intake is strongly influenced by local socio-cultural habits, in 
parallel with other nutritional components such as sodium.103 Collection of 24-hour urine 
samples importantly facilitates monitoring of a variety of dietary factors. Dietary 
interventions may reduce phosphate toxicity and FGF23 levels in healthy subjects104 as 
well as across stages of CKD patients, as reviewed elsewhere.105 Careful education of 
patients to avoid phosphate-containing food additives can result in partial correction of 
hyperphosphataemia.106 Furthermore, the dietary source of proteins determines the 
impact on phosphate homeostasis. CKD patients who consumed a vegetarian-based 
protein diet for 7 days presented with lower serum phosphate and FGF23 levels than 
those who received a meat-based protein diet.107 Unlike phosphate in meat, which is 
present as organic phosphate, the plant source of phosphate is phytic acid or phytate, 
which is not well hydrolyzed and only to a very limited extent absorbed by humans.108 In 
line, not only higher dietary phosphate intake but also higher dietary phosphate to 
protein ratios are each associated with increased death risk in maintenance 
hemodialysis patients.109 In addition, enhanced meat and poultry products may contain 
inorganic phosphate-containing additives that increase phosphate content by as much 
as two-fold compared to its additive-free counterparts.110  
The available data specifically addressing the impact of dietary modifications on 
phosphate metabolism after kidney transplantation is scarce. A recent study showed 
that patients with post-transplant hypophosphatemia had lower phosphate intake 
compared with patients with no hypophosphatemia.111 In the late post-transplant period, 
the diet may also affect outcomes after long-term kidney transplantation. We are not 
aware of any study addressing the impact of dietary phosphate restriction to reduce 
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hyperphosphatemia or FGF23 levels specifically in renal transplant recipients with 
impaired renal function, but it is reasonable to assume that findings in CKD patients can 
be extrapolated to the transplant population. 
 
Pharmacological interventions to reduce phosphate 
In early CKD patients with normal serum phosphate levels, the use of phosphate 
binders has been associated with improved control of secondary hyperparathyroidism 
by lowering serum FGF23 levels regardless the control of serum phosphate.112 Whether 
early correction of FGF23 levels results in reduced morbidity or mortality remains 
unclear. In the transplant population, phosphate binders have to be used with caution, 
given their effect on the availability of mycophenolate mofetil.113 With more advance 
renal function impairment, phosphate binders are generally used in line with the pre-
transplant CKD setting.114 Yet studies addressing the efficacy and safety of phosphate 
binders in renal transplant recipients are lacking, and no specific recommendations can 
be given as to whether calcium-containing or calcium-free binders should be used. 
Combining phosphate binder treatment with dietary phosphate restriction may well be 
the most efficient strategy to reduce serum phosphate as well as FGF23 levels.115  
Persistent hyperparathyroidism after transplantation, particularly when 
accompanied by hypercalcemia, can have detrimental effects on the graft, bone and the 
cardiovascular system. Treatment of hyperparathyroidism in renal transplant recipients 
can, however, be challenging. Vitamin D analogues can be effective to treat 
hyperparathyroidism,116-119 but are often avoided due to concurring hypercalcemia. The 
potential of cinacalcet, a calcimimetic drug, to treat hyperparathyroidism and correct 
46 
 
hypercalcemia in renal transplant recipients is being increasingly studied. Although 
cincalcet reduced both serum calcium and PTH in most studies, serum phosphate 
increased in some and remained stable in the other studies.120-124 Of note, cinacalcet 
may reduce the availability of tacrolimus, but not cyclosporine or mycophenolate, as 
suggested by a small uncontrolled study.125 In the absence of studies directly comparing 
cinacalcet with parathyroidectomy, cinacalcet is often used (off-label) in renal transplant 
recipients who do not have severe hypercalcemia, as an alternative to parathyroid 
surgery. 
Several novel compounds are currently under (pre-)clinical investigation for their 
phosphate-lowering capacity in CKD. Nicotinamide is an inhibitor of intestinal NaPi-2b 
transporters, and has been shown to reduce serum phosphate levels in CKD 
patients.119, 126 Another interesting drug is tenapanor, an inhibitor of the intestinal 
sodium-hydrogen exchanger 3, which was designed to reduce intestinal sodium intake 
for the treatment of volume overload, e.g. in heart failure and CKD. Interestingly, a 
recent study demonstrated that this compound is also able to reduce phosphate uptake 
as well as ectopic calcification in an animal model of CKD.127 In the future, these novel 
drugs, particularly in combination with established therapies such as phosphate binders, 
may contribute to the management of deregulated phosphate homeostasis in CKD 
patients, and possibly also in renal transplant recipients. 
 
Conclusions 
The clinical presentation of deregulated phosphate homeostasis in renal 
transplant recipients depends on many factors including the post-transplant stage, renal 
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function, and the immunosuppressive drug regimen. The early post-transplant phase is 
characterized by renal phosphate leak and hypophosphatemia, particularly promoted by 
the high capacity of the successfully transplanted kidney to excrete large amounts of 
phosphate in response to the persistently high circulating levels of FGF23 and PTH. 
Phosphate supplementation may be needed with deep hypophosphatemia (plasma 
phosphate <0.5 mmol/L or in symptomatic patients with serum phosphate <1.0 mmol/L), 
but must be undertaken with caution given the risk of exacerbated secondary 
hyperparathyroidism and, although incidentally reported, even nephrocalcinosis. In the 
setting of impaired graft function, the reduced capacity of the kidney to excrete 
phosphate, accompanied by high levels of PTH and FGF23, set the stage for an 
increased risk of cardiovascular complications, (aggravated) bone disease, and 
potentially also for progressive renal function loss. Dietary phosphate restriction and 
pharmacological interventions currently mainly consist of phosphate binders, aiming to 
prevent or reduce hyperphosphatemia and FGF23 levels after kidney transplantation. It 
should be taken into account that using phosphate binders could influence the 
bioavailability of mycophenolate mofetil. Novel agents targeting intestinal phosphate 
uptake are under way, and future studies are needed to investigate whether these 
agents are able to further improve phosphate control in renal transplant recipients with 
impaired graft function. The main question to be addressed, however, remains whether 
appropriate control of serum phosphate and FGF23 levels translates into clinically 





 Abnormalities in phosphate homeostasis are common in renal transplant recipients, 
and may range from hypophosphatemia early after transplantation to 
hyperphosphatemia, hyperparathyroidism, and high FGF23 levels late after 
transplantation 
 During the first months post-transplantation, persistent high levels of FGF23 and 
PTH despite restored renal function, immunosuppressive drugs, ischemia-
reperfusion injury and metabolic acidosis may concertedly result in post-transplant 
hypophosphatemia 
 Long-term exposure to high levels of phosphate and FGF23 may have distinct yet 
related adverse effects on the cardiovascular system, kidney and bone in renal 
transplant recipients 
 Although limited data specific to the renal transplant population are available, these 
patients are likely to benefit from dietary and pharmacological strategies to improve 
phosphate metabolism; future studies should address whether this improves 
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Background and objectives: Circulating fibroblast growth factor 23 (FGF23) is 
associated with adverse cardiovascular outcomes in chronic kidney disease. Whether 
FGF23 predicts cardiovascular mortality after kidney transplantation, independent of 
parameters of mineral metabolism and cardiovascular risk factors, is unknown.  
Design, setting, participants, and measurements: The association between plasma 
C-terminal FGF23 and cardiovascular mortality was analyzed in a single-center 
prospective cohort of 593 stable kidney transplant recipients (mean age 52±12 years, 
54% male, eGFR 47±16 ml/min/1.73 m2), at median 6.1 [2.7-11.7] years (median [IQR]) 
after transplantation). Multivariate Cox regression models were built, adjusting for 
parameters of renal function and mineral metabolism, Framingham risk factors, the left 
ventricular wall strain markers midregional fragment of pro-A-type natriuretic peptide 
(MR-proANP) and N-terminal-pro brain natriuretic peptic (NT-proBNP), and copeptin, 
the stable C-terminal portion of the precursor of vasopressin. 
Results: In multivariate linear regression analysis, MR-proANP (β=0.20, P<0.001), NT-
proBNP (β=0.18, P<0.001) and copeptin (β=0.26, P<0.001) were independently 
associated with FGF23. During follow-up for 7.0 [6.2-7.5] years, 128 patients (22%) 
died, of which 66 (11%) of cardiovascular disease; 54 (9%) had graft failure. FGF23 
was associated with an higher risk of cardiovascular mortality in a fully adjusted 
multivariate Cox-regression model (HR=1.88 (1.11-3.19), P=0.02). FGF23 was also 
independently associated with all-cause mortality (full model HR=1.86 (1.27-2.73), 
P=0.001). Net reclassification improved for both cardiovascular mortality (0.07 [95% CI 
0.01-0.14, P<0.05]) and all-cause mortality (0.11 [95% CI 0.05-0.18, P<0.001]). 
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Conclusions: Plasma FGF23 is independently associated with cardiovascular and all-
cause mortality after kidney transplantation. The association remained significant after 




Kidney transplantation is the treatment of choice for patients with end-stage renal 
disease. As a result of improved surgical techniques, immunosuppressive therapies, 
and prevention of opportunistic infections, especially the short-term prognosis of kidney 
transplant recipients has improved dramatically over the past decades. However, the 
risk of premature mortality due to cardiovascular disease remains greatly increased in 
kidney transplant recipients compared with the general population1. 
Deregulation of calcium/phosphate metabolism is common in chronic kidney 
disease (CKD) and in kidney transplant recipients with impaired renal function2. In CKD 
patients, circulating levels of fibroblast growth factor 23 (FGF23), parathyroid hormone 
(PTH) and phosphate have been identified as independent risk factors for 
cardiovascular disease and all-cause mortality3-9. Experimental studies demonstrated 
that FGF23 may be directly involved in the development of left ventricular hypertrophy 
(LVH)10. Whether FGF23 predicts cardiovascular mortality in renal transplant recipients 
is unknown. 
Our primary hypothesis was that plasma FGF23 is a risk factor for cardiovascular 
mortality in renal transplant recipients, independent of Framingham risk factors 
(recipient age and gender, systolic blood pressure, antihypertensive treatment use, 
smoking status, diabetes mellitus, plasma total cholesterol and HDL cholesterol), known 
correlates of FGF23 including eGFR and proteinuria11, and factors related to phosphate 
metabolism. We also addressed whether FGF23 is associated with the left ventricular 
wall strain markers midregional fragment of pro-A-type natriuretic peptide (ANP) and N-
terminal-pro brain natriuretic peptide (NT-proBNP), and with copeptin, the stable C-
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terminal portion of the precursor of vasopressin12, and whether these cardiac markers 
influence the association between FGF23 and cardiovascular mortality. 
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Materials and Methods 
Study population 
In this prospective cohort study, all renal transplant recipients with a graft 
functioning for at least one year who visited our outpatient clinic (University Medical 
Center Groningen, The Netherlands) between August 2001 and July 2003 were eligible 
to participate. This study was a post-hoc analysis of a previously published study13; 
plasma samples from 593 patients were available. All participants provided written 
informed consent. Patients were enrolled at median 6.1 [interquartile range 2.7-11.7] 
years after transplantation. Baseline visits were postponed if signs of infection were 
present. Patients diagnosed with cancer other than cured skin cancer were not eligible. 
The Institutional Review Board approved the study protocol (METc 01/039), which was 
in adherence to the Declaration of Helsinki. The clinical and research activities being 
reported are consistent with the Principles of the Declaration of Istanbul as outlined in 
the “Declaration of Istanbul on Organ Trafficking and Transplant Tourism”. 
 
Endpoints 
The major outcome of the study was cardiovascular mortality. All-cause mortality and 
death-censored graft failure were secondary outcomes. Adequate collection of up-to-
date data on events and mortality was ensured by our continuous surveillance system; 
general practitioners or referring nephrologists were contacted in case the current status 
of a patient was unknown. Cause of death was obtained by linking the number of the 
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death certificate to the primary cause of death as coded by a physician, according to the 
International Classification of Diseases, 9th revision (ICD-9). Cardiovascular death was 
defined as ICD-9 codes 410–44714. Follow-up was completed until May 19, 2009. There 
was no loss to follow-up. 
 
Patient characteristics and laboratory measurements 
Relevant transplant characteristics were taken from a database containing 
information on all renal transplantations performed at our center since 1968. Standard 
immunosuppressive treatment regimens are published previously13. Current medication 
including active vitamin D use (alfacalcidol or calcitriol), presence of diabetes mellitus, 
and cardiovascular history were extracted from the medical record. Diabetes mellitus 
was defined according to the American Diabetes Association guidelines: fasting plasma 
glucose ≥126 mg/dL or use of antidiabetic medication15. Cardiovascular history was 
defined as a history of myocardial infarction, percutaneous transluminal angioplasty or 
stenting of coronary or peripheral arteries, bypass operation of coronary or peripheral 
arteries, claudicatio intermittens, amputation for vascular reasons, transient ischemic 
attack, or ischaemic cerebrovascular accident. Blood pressure was measured as 
described previously13. Smoking status was recorded with a self-report questionnaire.  
Upon entry in the cohort (baseline), blood was drawn after an 8-12 hr overnight 
fasting period. EDTA plasma samples were stored at -80°C until assessment of 
biochemical parameters for this study. Plasma C-terminal FGF-23 levels were 
determined by sandwich ELISA (Immutopics, San Clemente, CA), with an intra-assay 
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and interassay coefficient of variation of < 5% and < 16% respectively16. Plasma 
creatinine concentrations were determined using a modified version of the Jaffe method 
(MEGA AU 510, Merck Diagnostic, Darmstadt, Germany). Parathyroid hormone and 
1,25(OH)2 vitamin D were measured in EDTA plasma using radioimmunoassay, and 
25(OH)-vitamin D levels were determined by isotope dilution–online solid phase 
extraction liquid chromatography–tandem mass spectrometry (ID-XLC–MS/MS)17. NT-
proBNP levels were measured by immunoassay on an ELECSYS2010 instrument 
(ELECSYS proBNP, Roche Diagnostics, Germany). MR-proANP was measured with a 
sandwich immunoassay (MR-proANP LIA; B.R.A.H.M.S)18. Plasma copeptin was 
measured using a sandwich immunoassay (B.R.A.H.M.S GmbH/Thermo Fisher 
Scientific, Hennigsdorf/Berlin, Germany)19. Serum albumin, calcium, cholesterol, C-
reactive protein, glucose, hemoglobin, phosphate, and urinary phosphate, sodium, total 
protein and urea were determined by routine laboratory measurements. Estimated GFR 
(eGFR) was calculated using the CKD-EPI formula20. 
 
Statistical analyses 
Variable distribution was tested with histograms and probability plots. Normally 
distributed variables are presented as mean±standard deviation, and skewed variables 
as median [first-third quartile]. Baseline characteristics upon entry into the cohort were 
compared between tertiles of FGF23 using one-way ANOVA, Kruskal-Wallis test, and ×2 
tests as appropriate. Skewed data were natural log-transformed for correlation analysis, 
Cox regression, backward and forward linear analysis. 
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The associations between (log-transformed) FGF23 levels and MR-proANP, NT-
proBNP and copeptin were assessed by Pearson correlation analysis. Backward linear 
regression was used to identify correlates of plasma FGF23 levels. The following 
covariates were tested: age, gender, donor type (deceased or living), history of one or 
more acute rejection episodes, cold ischemia time, waist circumference, cardiovascular 
history, Framingham risk score factors, eGFR, proteinuria, serum phosphate, 24-h 
urinary phosphate excretion (representing phosphate intake), 24-h urinary urea 
excretion (representing protein intake21), plasma 25(OH)-vitamin D, 1,25(OH)2 vitamin 
D, PTH, CRP, albumin, hemoglobin, MR-proANP, NT-proBNP and copeptin levels, use 
of ACE inhibitor or angiotensin receptor blocker (given potential interactions between 
RAAS and FGF2322), use of active vitamin D, and number of antihypertensive drugs. 
Variables significantly associated with FGF23 levels using backward linear regression 
analysis were subsequently tested in a forward linear regression model. Variables that 
were significant in this model were considered independent correlatesof FGF23 levels.  
Risk ratios and conditional maximum likelihood estimates of the rate ratio for 
cardiovascular and all-cause mortality and graft failure were calculated per tertile of 
FGF23. Confidence intervals were calculated using the Fisher Exact test. To further 
analyze the association between FGF23 and outcomes, tertiles of FGF23 were plotted 
in Kaplan Meier curves with log rank test. Subsequently, multivariate Cox regression 
models were built to assess the association between FGF23 and outcomes, adjusted 
for potential confounders. We tested for effect modifications by invoking multiplicative 
interaction terms. Sensitivity analyses were performed in a predefined subgroup of 
patients with an eGFR between 30 and 90 mL/min (n=493). 
74 
 
To determine the goodness of fit of the predictive models, the Akaike Information 
Criterion (AIC) was used. AIC is a statistical estimate of the trade-off between the 
likelihood of a model against its complexity. A lower value of AIC indicates a better 
model fit. Furthermore discrimination, or the ability of the risk prediction models to 
distinguish those with an event (i.e. cardiovascular or all-cause mortality or graft failure) 
from those who do not, was evaluated with Harrell’s C-index. Harrell’s C-index is 
analogous to the area under the receiver operating characteristic curve, for which larger 
values indicate better discrimination.  
We assessed net reclassification improvement (NRI) for predefined risk 
categories of cardiovascular and all-cause mortality (<5%, 5% to 10%, and >10%), and 
calculated integrated discrimination improvement (IDI)23. The NRI provides 
reclassification tables constructed separately for study participants with and without 
events, and quantifies the correct movement between categories – upwards for events 
and downwards for non-events. 
Proportionality assumptions were tested using Schoenfeld tests and log-minuslog 
survival plots. All statistical analyses were performed using SPSS 16.0 for Windows 
(IBM, Armonk, NY), Stata/SE 11.0 for Windows (College Station, TX) and OpenEpi 





Patient characteristics are summarized in Table 1. Overall, FGF23 levels were 
140 [95-219] RU/mL, and eGFR was 47±16 mL/min per 1.73 m2. None of the patients 
used dietary phosphate binders. Patients in the highest FGF23 tertile were older, were 
more likely to have received a graft from a deceased donor, more likely to have had an 
acute rejection episode and more likely to be a smoker, had a longer cold ischemia 
time, higher waist circumference, systolic and diastolic blood pressure, had worse renal 
function, lower serum albumin, HDL cholesterol, 1,25(OH)2 vitamin D and hemoglobin, 
and higher serum phosphate, NT-proBNP, MR-proANP, copeptin, PTH, and CRP levels 
and more proteinuria. 
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Table 1. Clinical characteristics of the cohort* 
                  Plasma FGF23 tertiles 
 All patients Tertile 1 Tertile 2 Tertile 3 P 
 n=593 n=197 n=198 n=198  
Plasma C-terminal FGF23 (RU/mL) 140 (95-219) 83 (68-96) 141 (124-162) 311 (220-567) <0.001 
      
Age, years 52 ± 12 50 ± 13 52 ± 12 53 ± 11 0.04 
Male sex 54% 56% 51% 55% 0.62 
Caucasian race 95% 94% 94% 95% 0.41 
Etiology of kidney disease     0.75 
   Primary glomerulonephritis 28% 26% 30% 29%  
   Glomerulonephritis due to vasculitis / 
   auto-immune disease 
6% 9% 5% 6%  
   Tubulo-interstitial nephritis / 
   pyelonephritis 
16% 20% 15% 14%  
   Polycystic kidney disease 18% 16% 18% 20%  
   Hypertension 6% 7% 5% 5%  
   Diabetes 3% 4% 3% 3%  
   Other / unknown 23% 18% 24% 23%  
Dialysis duration, months 27 (13-48) 24 (13-43) 31 (14-48) 26 (13-52) 0.40 
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Deceased donor transplant 86% 78% 92% 91% <0.001 
Cold ischemia time, hours 22 (15-27) 20 (7-27) 22 (16-26) 22 (16-29) 0.04 
Total warm ischemia time, minutes 35 (30-45) 35 (30-45) 35 (30-45) 36 (30-45) 0.92 
Total number of HLA mismatches 1 (0-2) 1 (0-2) 1 (0-2) 1 (0-2) 0.41 
History of acute rejection 45% 39% 44% 52% 0.04 
Transplant vintage, years 6.1 (2.7-11.7) 5.6 (2.4-11.1) 5.8 (3.0-11.5) 7.2 (3.5-12.2) 0.06 
Waist circumference, cm 97 ± 14 94 ± 13 97 ± 14 100 ± 13 <0.001 
Systolic BP, mmHg 153 ± 23 148 ± 21 153 ± 22 157 ± 25 <0.001 
Diastolic BP, mmHg 90 ± 10 89 ± 10 89 ± 9 91 ± 10 <0.001 
Current smoker 22% 18% 18% 30% <0.001 
Current diabetes 18% 19% 17% 18% 0.88 
Laboratory results      
 Measurements in serum/plasma      
   creatinine, mg/dL 1.5 (1.3-1.9) 1.4 (1.1-1.6) 1.5 (1.3-1.7) 1.9 (1.4-2.5) <0.001 
   albumin, g/dL 4.1 ± 0.3 4.1 ± 0.3 4.1 ± 0.4 4.0 ± 0.3 <0.001 
   calcium, mg/dL 9.6 ± 0.6 9.5 ± 0.6 9.6 ± 0.7 9.6 ± 0.7 0.20 
   total cholesterol, mg/dL 218 ± 42 214 ± 35 219 ± 38 221 ± 51 0.13 
   HDL cholesterol, mg/dL 42 ± 12 45 ± 13 42 ± 12 40 ± 12 <0.001 
   LDL cholesterol, mg/dL 137 ± 39 137 ± 31 136 ± 39 138 ± 46 0.84 
   NT-proBNP, pg/mL 299 (131-672) 180 (92-419) 285 (130-567) 457 (240-1517) <0.001 
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   MR-proANP, pmol/L 164 (103-275) 126 (87-188) 153 (100-231) 257 (158-390) <0.001 
   Copeptin, pmol/L 9.3 (5.0-19.5) 6.5 (3.8-10.4) 8.6 (4.7-17.4) 16.1 (7.7-30.0) <0.001 
   C-reactive protein, mg/l 2.1 (0.8-4.9) 1.7 (0.6-3.7) 2.1 (0.8-4.5) 3.0 (1.2-7.8) <0.001 
   glucose, mg/dL 87 ± 23 86 ± 22 87 ± 26 88 ± 20 0.59 
   phosphate, mg/dL 3.3 ± 0.7 3.1 ± 0.6 3.2 ± 0.6 3.6 ± 0.7 <0.001 
   parathyroid hormone, pg/mL 86 (57-131) 72 (51-112) 88 (61-121) 101 (68-193) <0.001 
   25-OH vitamin D, ng/mL 21 ± 9 22 ± 10 21 ± 8 22 ± 10 0.49 
   1,25-OH2 vitamin D, pg/mL 42 ± 18 47 ± 17 42 ± 19 35 ± 15 <0.001 
   hemoglobin, g/dL 13.7 ± 1.5 14.2 ± 1.3 13.8 ± 1.3 13.1 ± 1.7 <0.001 
   estimated GFR (CKD-EPI), mL/min/1.73m2 47 ± 16 55 ± 13 48 ± 14 37 ±15 <0.001 
 Measurements in 24h-urine      
   sodium excretion, mEq/24h 140 ± 68 139 ± 68 138 ± 61 143 ± 75 0.66 
   phosphate excretion, g/24h 2.3 ± 0.8 2.3 ± 0.9 2.4 ± 0.8 2.2 ± 0.8 0.18 
   proteinuria, g/24h 0.2 (0.0-0.5) 0.2 (0.0-0.3) 0.2 (0.0-0.4) 0.3 (0.2-0.8) <0.001 
   urea excretion, g/24h 10.5 ± 3.2 10.6 ± 3.1 10.9 ± 3.2 10.0 ± 3.2 0.03 
Medication      
   Ca supplements 7% 5% 6% 10% 0.07 
   Active vitamin D (alfacalcidol or calcitriol) 9% 8% 5% 14% 0.02 
   ACE inhibitor or ARB 34% 30% 34% 39% 0.17 
   Prednisone dose, mg/day 10 (7.5-10) 10 (7.5-10) 10 (7.5-10) 10 (7.5-10) 0.58 
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   Calcineurin inhibitor 78% 77% 83% 75% 0.12 
   Azathioprine 34% 29% 34% 38% 0.17 
   Mycophenolate mofetil 40% 49% 41% 31% <0.001 
   Sirolimus 2% 2% 2% 2% 0.88 
*All variables were determined at enrollment except gender, race, etiology of the original kidney disease, cold ischemia 




FGF23 is independently associated with cardiac markers . Plasma FGF23 levels were 
associated with NT-proBNP (r2=0.12, P<0.001), MR-proANP (r2=0.18, P<0.001), and 




Using backward and forward multivariate linear regression models, we found that 
copeptin was strongly and independently associated with plasma FGF23 levels (Table 
2). Other independent correlates of FGF23 levels were eGFR, serum phosphate, 
hemoglobin, and donor type (living or deceased). Results were highly similar when 
instead of copeptin, MR-proANP (coefficient 0.20 (0.12 to 0.28), P<0.001) or NT-
proBNP (coefficient 0.18 (0.11 to 0.25), P<0.001) were forced into the final forward 
regression model. 
Table 2. Multivariate linear regression analysis for correlates of plasma FGF23 
levels 
Parameter Coefficient for FGF23 (95% CI) p 
eGFR (CKD-EPI) -0.32 (-0.41 to -0.23) <0.001 
Ln copeptin 0.26 (0.17 to 0.35) <0.001 
Serum phosphate 0.15 (0.07 to 0.23) <0.001 
Hemoglobin -0.14 (-0.22 to -0.06) <0.001 
Donor type (0=living; 1=deceased) -0.10 (-0.18 to -0.03) 0.004 
Excluded from the model: age, gender, history of one or more acute rejection episodes, 
cold ischemia time, waist circumference, cardiovascular history, systolic and diastolic 
blood pressure, smoking status, diabetes mellitus, total cholesterol, proteinuria, 24-
urinary phosphate and urea excretion, plasma 25(OH)-vitamin D, 1,25(OH)2 vitamin D, 
CRP, albumin, and parathyroid hormone levels, use of ACE inhibitor or angiotensin 
receptor blocker, use of active vitamin D, and total number of antihypertensive drugs. 




Baseline plasma FGF23 and outcomes 
During follow-up of 7.0 [6.2-7.5] years, 128 patients (22%) died, 66 (11%) of 
cardiovascular disease, and 54 (9%) had graft failure. Kaplan Meier survival plots 
demonstrated a  higher risk of cardiovascular mortality, all-cause mortality and graft 
failure per increasing tertile of plasma FGF23 (Figure 2). Risk ratios for cardiovascular 
mortality, all-cause mortality and graft failure were significantly increased in the highest 
FGF23 tertile (Table 3). In Cox regression models, the highest tertile of FGF23 was 
consistently associated with a higher risk of cardiovascular mortality after adjustment for 
Framingham risk factors, history of cardiovascular disease, parameters of renal 







Table 3. Events and risk rtios for cardiovascular and all-cause mortality and graft failure per FGF23 tertile 
  Plasma FGF23 tertiles   
 All patients Tertile 1 Tertile 2 Tertile 3 P*  
Cardiovascular mortality       
  Events / patient-years 66 / 3722 11 / 1343 17 / 1260 38 / 1119   
  Incidence rate/1000 person-yrs 17.7 8.2 13.5 34.0   
  Risk ratio (95% CI)  Reference 1.65 (0.73-3.89) 4.15 (2.08-8.99) <0.001  
       
All-cause mortality       
  Events / patient years 128 / 3722 24 / 1343 33 / 1260 71 / 1119   
  Incidence rate/1000 person-yrs 34.4 17.9 26.2 63.4   
  Risk ratio (95% CI)  Reference 1.47 (0.84-2.59) 3.55 (2.21-5.90) <0.001  
 
Graft failure 
      
  Events / patient years 54 / 3722 8 / 1343 8 / 1260 38 / 1119   
  Incidence rate/1000 person-yrs 14.5 6.0 6.3 34.0   




Table 4.  Cox regression analyses for cardiovascular and all-cause mortality and graft failure per fibroblast growth factor 23 
tertile or per 1 SD of natural log fibroblast growth factor 23 
Model 1: crude model; model 2: adjusted for estimated GFR (CKD-Epidemiology Collaboration formula) and proteinuria; model 3: model 2 + adjusted for 
cardiovascular disease history, Framingham risk factors (recipient age and sex, systolic BP, antihypertensive treatment use, smoking status, diabetes mellitus, 
plasma total cholesterol, and HDL cholesterol), and transplant vintage; model 4: model 3 + adjusted for serum phosphate, 1,25(OH)2-vitamin D, parathyroid 
hormone levels, and active vitamin D use; model 5: model 4 + adjusted for N-terminal-pro brain natriuretic peptide, pro–A-type natriuretic peptide, and copeptin. 
HR, hazard ratio; CI, confidence interval; AIC, Akaike information criterion. aP for linear trend. 
 
 
Variable Plasma FGF23 Tertiles Natural Log FGF23 
Tertile 1      Tertile 2         Tertile 3      P Valuea Per 1 SD      P Value AIC Harrell C-Index 
Cardiovascular mortality,             
HR (95% CI)     
,0.001 
   
,0.001 
  
Model 1 Reference 1.66 (0.78 to 3.54) 4.24 (2.17 to 8.29) 1.97 (1.52 to 2.55) 645 0.706 
Model 2 Reference 1.62 (0.75 to 3.50) 4.02 (1.90 to 8.50) ,0.001 1.98 (1.44 to 2.74) ,0.001 648 0.706 
Model 3 Reference 1.39 (0.55 to 3.50) 4.20 (1.90 to 9.81) ,0.001 1.93 (1.33 to 2.80) 0.001 800 0.801 
Model 4 Reference 1.59 (0.58 to 4.14) 4.06 (1.55 to 9.98) 0.003 2.27 (1.37 to 3.75) 0.001 479 0.810 
Model 5 Reference 1.86 (0.67 to 5.18) 2.96 (1.06 to 8.26) 0.04  1.88 (1.11 to 3.19) 0.02 467 0.843 
All-cause mortality,             
HR (95% CI)     
,0.001 
   
,0.001 
  
Model 1 Reference 1.47 (0.87 to 2.48) 3.64 (2.29 to 5.78) 1.99 (1.65 to 2.39) 1245 0.694 
Model 2 Reference 1.36 (0.80 to 2.32) 2.94 (1.73 to 4.98) ,0.001 1.86 (1.46 to 2.36) ,0.001 1237 0.693 
Model 3 Reference 1.03 (0.55 to 1.93) 3.15 (1.69 to 5.85) ,0.001 1.93 (1.45 to 2.56) ,0.001 1542 0.768 
Model 4 Reference 1.06 (0.53 to 2.11) 2.63 (1.32 to 5.24) 0.004 2.18 (1.50 to 3.18) ,0.001 869 0.778 
Model 5 Reference 1.17 (0.58 to 2.36) 2.23 (1.11 to 4.49) 0.02  1.86 (1.27 to 2.73) 0.001 858 0.799 
Graft failure, HR (95% CI)     
,0.001 
   
,0.001 
  
Model 1 Reference 1.06 (0.40 to 2.83) 6.29 (2.92 to 13.44) 3.37 (2.56 to 4.42) 515 0.762 
Model 2 Reference 0.54 (0.20 to 1.46) 1.15 (0.47 to 2.84) 0.41  1.49 (0.99 to 2.24) 0.06 463 0.861 
Model 3 Reference 0.53 (0.18 to 1.57) 0.80 (0.29 to 2.24) 0.99  1.15 (0.73 to 1.82) 0.55 540 0.885 
      Model 4 Reference 0.35 (0.10 to 1.22) 0.39 (0.12 to 1.30) 0.25  1.00 (0.59 to 1.71) 0.99 327 0.907 
Model 5 Reference 0.32 (0.09 to 1.21) 0.37 (0.11 to 1.32) 0.25  1.03 (0.59 to 1.78) 0.93 331 0.909 
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To assess whether the association between FGF23 and cardiovascular mortality 
was influenced by other factors, interaction analyses were performed. We found no 
evidence for interaction in the association between FGF23 and cardiovascular mortality 
by eGFR (P for interaction=0.51), proteinuria (P=0.62), 24h-urinary phosphate excretion 
(P=0.50), fractional phosphate excretion (P=0.87) or any Framingham risk factor. In 
addition, no significant interaction by NT-proBNP (P for interaction=0.26), MR-proANP 
(P=0.32), and copeptin (P=0.19) was observed. NT-proBNP and MR-ANP but not 
copeptin were independently associated with cardiovascular mortality in the full model 
(data not shown). The final models provided the best fit (lowest AICs); all models 
displayed good discrimination as suggested by relatively high Harrell’s C-indices (Table 
4). As a sensitivity analysis, full multivariate Cox regression models were repeated in a 
subgroup of patients with an eGFR between 30 and 90 mL/min (n=493). In this 
subgroup, plasma FGF23 remained an independent risk factor for cardiovascular 
mortality (full model hazard ratio 2.43 (95% CI 1.19-4.93) per 1 SD of lnFGF23, P=0.01) 
and all-cause mortality (2.12 (1.29-3.49) per 1 SD of lnFGF23, P=0.003). 
Higher FGF23 levels were also associated with a higher risk of all-cause 
mortality, both when analyzed per tertile and as continuous variable (Table 4). Higher 
tertiles of FGF23 were also associated with a higher risk of death-censored graft failure 
in crude analyses, but significance was lost after adjustment for eGFR and proteinuria 
(Table 4). There was no significant interaction between the risk of graft failure and 





To compare the performance of FGF23 with other parameters of mineral 
metabolism (fractional phosphate excretion, PTH, phosphate, 25-OH vitamin D or 
1,25(OH)2 vitamin D) as individual predictors of cardiovascular mortality, separate Cox 
regression analyses were performed for each of the six exposures, adjusted for age, 
gender, cardiovascular history, eGFR, proteinuria, and Framingham risk factors. As 
indicated in Figure 3, FGF23 (highest tertile HR 3.45 (1.57-7.58), P=0.001) but not the 
other exposures were strongly associated with cardiovascular mortality. 
 
NRI and IDI 
The NRI was calculated to assess the putative clinical utility of FGF23 as a 
marker of (cardiovascular) mortality in addition to Framingham risk factors. 
Reclassification improved mainly in the patients who survived, where adding FGF23 to 
the model resulted in reclassification into a lower risk category (Table 5). Overall, net 
reclassification improved for both cardiovascular mortality (0.07 [95% CI 0.01-0.14, 
P<0.05]) and all-cause mortality 0.11 (95% CI 0.05-0.18, P<0.001). Accordingly, the IDI, 
which does not rely on prespecified risk categories but represents a continuous 
measure, was 0.03 (95% CI 0.01-0.05, P=0.004) for cardiovascular mortality and 0.05 




Table 5.  Reclassification based on fibroblast growth factor 23 levels 
Without FGF23 With FGF23 (n) Total (n) 



















Estimated risk of cardiovascular mortalitya       
 




 5%  2   
 
 5%–10%   6    
 
10%    2c 55 
 
Total 2 9  55 
 
Patients without cardiovascular mortality   
12c 1c 
 
5%  186 
 
5%–10%  46b 75  15c 
 
         10%    27b 15 
 
Total 232 114  167 
 
Estimated risk of all-cause mortalityd       
 
Patients with all-cause mortality   
1b 1b 
 
         5%  1 
 
         5%–10%  3c 3  2b 
 
         10%    3c 114 
 
Total 4 7  117 
 




   5%  92   
 
   5%–10%  24b 41  9c 
 
  10%   5b 44b 230 
 
  Total 121 91  239 
 
Multivariate model adjusted for Framingham risk factors (recipient age and sex, systolic BP, antihypertensive treatment use, 
smoking status, diabetes mellitus, plasma total cholesterol and HDL cholesterol) with or without plasma C-terminal fibroblast 
growth factor 23 level. FGF23, fibroblast growth factor 23. 
aNet reclassification improvement was 0.07 (95% confidence interval [CI], 0.01 to 0.14; 
P,0.05). bNumbers of patients who were correctly reclassified by the model with FGF23. 
cNumbers of patients who were incorrectly reclassified by the model with FGF23. 





This study identified high plasma FGF23 levels as an independent risk factor for 
cardiovascular mortality in kidney transplant recipients. The association was consistent 
in regression models adjusted for renal function, parameters of mineral metabolism, and 
cardiovascular risk factors. The significantly improved net reclassification index 
suggests that FGF23 levels may have an additional value to Framingham risk factors to 
predict the risk of cardiovascular mortality in renal transplant recipients.  
Our findings are in line with previous data linking high FGF23 levels with incident 
cardiovascular disease and mortality in the CKD population3,24-25, and with a higher risk 
of all-cause mortality after kidney transplantation26. Furthermore FGF23 levels have 
been associated with established cardiovascular risk factors and with a higher risk of 
cardiovascular events in the general population27-28. Although patients in the highest 
FGF23 tertile were characterized by an overall high cardiovascular risk profile, the 
associations between FGF23 and (cardiovascular and all-cause) mortality remained 
significant after adjusting for several major cardiovascular risk markers including 
Framingham risk factors, suggesting that FGF23 is a strong and independent risk 
marker. The potential clinical relevance of FGF23 in addition to established risk markers 
is further supported by improved reclassification (NRI and IDI). Furthermore, FGF23 but 
not serum phosphate, PTH or vitamin D levels were independently associated with 
cardiovascular mortality (Figure 3), suggesting a specific role for FGF23. Initially the 
observed association between elevated FGF23 levels and a higher cardiovascular risk 
positioned FGF23 as a biomarker of phosphate toxicity. More recently, animal studies 
demonstrated that FGF23 has ‘off-target’ effects, directly contributing to the 
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development of LVH (10). We found that FGF23 was independently associated with 
MR-proANP and NT-proBNP, both markers of left ventricular wall strain, and with 
copeptin, a stable peptide derived from the vasopressin precursor29. All three cardiac 
markers are used as markers of heart failure30. Although these associations are in line 
with a potential role for FGF23 in LVH, we could not demonstrate modulation of the 
association between FGF23 and cardiovascular mortality by these cardiac markers. 
Furthermore, only a small amount of FGF23 was explained by copeptin, MR-proANP 
and NT-proBNP (Figure 1), suggesting that FGF23 is independently related to 
cardiovascular and all-cause mortality. 
In a previous study, the association between FGF23 and cardiovascular events 
was modified by gender31. We could not confirm this effect modulation, which could be 
explained by differences in renal function between the Heart and Soul study (eGFR 
71±23 mL/min/1.73 m2) and our cohort (eGFR 47±16 mL/min/1.73 m2). Data from 24h-
urine collections allowed us to include phosphate intake (assessed by 24h-urinary 
phosphate excretion)32 and excretion (fractional phosphate excretion) in our analyses. 
Both parameters did not interact with the association between FGF23 levels and 
cardiovascular mortality.  
FGF23 was also associated with a higher risk of graft failure in univariate 
analysis, in line with a previous study26. However, the association was no longer 
significant after adjusting for eGFR and proteinuria in addition to known risk factors for 
graft failure (Table 3). We hypothesize that renal function after transplantation has a 
stronger impact on the risk of graft failure than on the risk of mortality33-34.  
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Possible limitations of our study include its post hoc nature and the use of ICD-9 
codes rather than an independent adjudication committee to define the endpoint 
cardiovascular mortality. Although we adjusted for several confounders including 
parameters of renal function, which appeared to be the most important determinant of 
FGF23 levels, the possibility of residual confounding cannot be fully excluded, as not all 
determinants of FGF23 are currently known. The sensitivity analyses in patients with an 
eGFR of 30-90 mL/min/1.73 m2 reduces the risk of confounding by renal function. The 
fact that diabetic and hypertensive nephropathy were under-represented in our cohort, 
and that our cohort consisted almost entirely of Caucasians limits the generalizability of 
our study. Since FGF23 was only measured at a single time point in this cohort we 
could not perform a repeated measures analysis. Prevalent cohorts such as this may 
suffer from survivorship biases; these generally lead to an underestimation of the 
hazard ratio35. Using a relatively large number of covariates in the final Cox regression 
model might result in overfitting the model; however the stepwise Cox models and the 
low AIC in the final model suggest that overfitting was no issue in our analyses. Finally, 
we did not have extensive structural or functional cardiac data (e.g. from 
echocardiography) available to further explore the mechanisms behind the observed 
association between FGF23 and cardiovascular mortality. Strong points of this study, on 
the other hand, are the use of 24-hour urine collections which enabled us to adjust for 
proteinuria and phosphate excretion, the availability of multiple markers of 
cardiovascular risk, and the complete follow-up.  
In conclusion, to our knowledge this is the first study to identify FGF23 as an 
independent risk factor for cardiovascular mortality after kidney transplantation. 
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Although it may be relevant to consider therapies reducing FGF23 levels36  to improve 
cardiovascular outcomes, it should be kept in mind that high FGF23 levels may serve 
an important physiological goal, namely to keep phosphate balance. A recent study 
demonstrated that specific FGF23 blockade with a neutralizing antibody did reduce 
secondary hyperparathyroidism but increased serum phosphate, aortic calcification and 
mortality37. Whether specific reduction of FGF23 or rather reducing phosphate load may 
improve cardiovascular prognosis after kidney transplantation should be addressed in 
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Background and Aims: A high circulating fibroblast growth factor 23 (FGF23) level is 
an independent risk factor for cardiovascular mortality in renal transplant recipients and 
the general population. N-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic 
acid (DHA) may contribute to cardiovascular risk reduction. We investigated whether 
fish and EPA-DHA intake are related to FGF23 levels in renal transplant recipients. 
Methods and results: We performed a cross-sectional analysis in 619 stable renal 
transplant recipients (mean age 53 years, 57% male, estimated glomerular filtration rate 
[eGFR] 53±20 mL/min/1.73m2). Dietary intake was assessed by a 177-item food 
frequency questionnaire. Serum intact FGF23 was measured by ELISA. We examined 
differences in FGF23 levels across categories of fish and EPA-DHA intake using 
analysis of variance models adjusted for age, sex, dietary and lifestyle factors and key 
determinants of FGF23. Patients consumed on average 15 g of fish and 139 mg EPA-
DHA/day. Median FGF23 was 62 pg/mL (IQR 43-98 pg/mL). Higher dietary EPA-DHA 
and fish intake were associated with lower serum FGF23 levels. Subgroup analyses 
revealed that particularly in patients with reduced renal function (eGFR 
<60mL/min/1.73m2), adjusted FGF23 levels (114, 79, 75 pg/mL, P=0.0001) were 
inversely associated with tertiles of EPA-DHA intake. Similarly, we observed an inverse 
association between fish consumption and serum FGF23 levels in adjusted analyses.  
Conclusion: A higher intake of fish and dietary n-3 fatty acids (EPA-DHA) is related to 
lower circulating FGF23 levels in renal transplant recipients. Further research is needed 




Chronic kidney disease (CKD) is a worldwide health burden, affecting about 15% 
of the Western adult population. For most patients with end-stage renal disease, kidney 
transplantation is the preferred treatment. Although short-term graft and patient survival 
have improved impressively over the past decades, cardiovascular disease limits long-
term patient survival 1. Both the incidence and prevalence of cardiovascular disease are 
several times higher in renal transplant recipients than in the general population 2. 
In patients with impaired renal function, deregulated phosphorus metabolism 
characterized by elevated circulating levels of the phosphaturic hormone fibroblast 
growth factor 23 (FGF23) plays a specific role in the pathophysiology of cardiovascular 
disease. In response to – particularly inflammatory – renal injury, the renal expression of 
Klotho, a mandatory cofactor for the specific FGF23 receptor, is lost 3 which may 
contribute to increased circulating FGF23 levels4. Besides being an indicator of impaired 
renal function and disturbed phosphorus metabolism, high circulating FGF23 levels may 
also directly contribute to the development of left ventricular hypertrophy5. Many 
epidemiologic studies have identified a high FGF23 level as an independent risk factor 
of cardiovascular disease and all-cause mortality in the general population6, across 
stages of CKD7, and in renal transplant recipients8-9. Consequently, strategies to reduce 
FGF23 levels may have clinical impact.  
Patients with impaired renal function have lower serum levels of the n-3 fatty 
acids eicosapentaenoic (EPA) and docosahexaenoic acid (DHA), mainly consumed 
through fish, which may be linked to a higher cardiovascular disease risk in these 
patients10. Randomized controlled trials in patients with chronic kidney disease (CKD) 
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showed a decrease in serum inflammatory markers after EPA-DHA supplementation11. 
Given the role of FGF23 as a cardiovascular risk factor in renal patients and the 
potential cardioprotective and anti-inflammatory effects of n-3 fatty acids, we 
investigated whether intake of fish and EPA-DHA are related to serum FGF23 levels in 






We conducted a cross-sectional analysis in a large, single center renal transplant 
recipient cohort. We invited all renal transplant recipients (≥ 18 years) with a functioning 
graft for at least one year, who visited our outpatient clinic between November 2008 and 
March 2011. Renal patients had all been transplanted in the University Medical Center 
Groningen. They had sufficient knowledge of the Dutch language and no history of drug 
or alcohol addiction. Of 817 initially invited patients, 707 (87%) signed written informed 
consent to participate in this study. After exclusion of patients with missing data on 
dietary n-3 fatty acids (n=82), missing data on eGFR (n=2) and FGF23 concentrations 
(n=4), data from 619 patients were available for analyses. The Institutional Review 
Board on human experimentation approved the study protocol (METc 2008/186), which 
was in adherence to the Declaration of Helsinki. The routine regimen included no 
specific dietary counseling, except for discouraging excess sodium intake and 
encouraging losing weight in overweight individuals. Renal transplant recipients were on 
standard antihypertensive and immunosuppressive therapy, which was as previously 
described12. Data on current medication including vitamin D supplementation 
(cholecalciferol, alfacalcidol or paricalcitol) was extracted from the medical records. 
 
Dietary assessment 
All patients adhered to their regular dietary habits during examination. Dietary 
intake was assessed using a semi quantitative food frequency questionnaire (FFQ) 
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which has been validated as described previously13. The FFQ inquired about intake of 
177 food items during the last month. For each item, the frequency was recorded in 
times per day, week, or month, and seasonal variations were taken into account. The 
number of servings was expressed in natural units (for example, slice of bread or apple) 
or household measures (for example, cup or spoon). The questionnaire was self-
administered and filled out at home. At the day of the visit to the outpatient clinic, all 
FFQs were checked for completeness by a trained researcher and inconsistent answers 
were verified with the patients. Total energy and nutrient intake per day was calculated 
using Dutch Food Composition Tables14. Additionally, all participants were instructed to 
collect a 24-hour urine sample according to a strict protocol. Sodium intake was 
estimated from 24-h urine sodium excretion and the accuracy of FFQ for protein intake 
estimation was inferred by correlating protein intake with the protein equivalent of 
nitrogen appearance (PNA)15. 
 
Clinical and biochemical parameters  
Information on patient`s health status and medical history was obtained from 
patient records. Patients received state-of-the art treatment (Table 1), and data on 
current medication was extracted from the medical records. Body weight and height 
were measured while participants wore indoor clothing without shoes. Body Mass Index 
(BMI) was calculated as weight divided by height squared (kg/m2). Blood pressure (BP) 
was measured as described previously16. Hypertension was defined as BP ≥ 140/90 
mmHg or use of antihypertensive medication). Diabetes mellitus was considered 
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present when serum glucose was above 7 mmol/l (126 mg/dl) or when the patient used 
antidiabetic medication.  
Blood was drawn after an 8-12h overnight fasting period in the morning after 
completion of the 24h urine collection. Urinary and plasma concentrations of sodium, 
chloride, potassium, calcium, phosphate and urea were measured using routine clinical 
laboratory methods as were plasma hsCRP, total cholesterol, HDL cholesterol, LDL 
cholesterol, triglycerides and albumin. Intact parathyroid hormone (PTH) was measured 
in EDTA plasma using radioimmunoassay. Serum creatinine level was determined 
using a modified version of the Jaffé method (MEGA AU 510, Merck Diagnostica, 
Darmstadt, Germany). Renal function was assessed by calculating the estimated 
glomerular filtration rate (eGFR) applying the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation17. Urinary albumin concentration was determined by 
nephelometry (Dade Behring Diagnostic, Marburg, Germany). Total urinary protein 
concentration was analyzed using the Biuret reaction (MEGA AU 510, Merck 
Diagnostica, Darmstadt, Germany). Serum intact FGF23 levels were determined using 
a commercially available ELISA kit (Kainos Laboratories, Inc., Tokyo, Japan). Intra- and 
interassay CVs are <10% and <14%, respectively18. 
 
Statistical analysis 
Statistical analyses were performed using Stata (version 11.0, StataCorp, 
College Station, Texas, USA) and SAS statistical packages (version 9.3, SAS Institute, 
Cary, North Carolina, USA). A two sided p-value <0.05 was considered statistically 
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significant. Because the intakes of EPA and DHA were highly correlated (Spearman 
correlation coefficient: 0.99) the sum of EPA and DHA was used in the analyses.  
Descriptive analyses were performed to calculate mean and standard deviations 
(SD) or medians and interquartile range (IQR: p25, p75). Differences in baseline 
variables among different categories of n-3 fatty acid consumers were evaluated by 
using the Kruskal-Wallis test for skewed variables, the analysis of variance (ANOVA) for 
normally distributed continuous variables and Chi-squared test for categorical data. The 
association between EPA-DHA intake and lipid profile (i.e. total, HDL, or LDL 
cholesterol or triglyceride levels) was studies using Spearman correlation analysis. 
Backward linear regression was used to identify correlates of plasma FGF23 
levels. The following covariates were tested: age, sex, donor type (deceased or living), 
warm and cold ischemia times, BMI, cardiovascular history, Framingham risk score 
factors, eGFR, albuminuria, serum phosphate, 24-hour urinary phosphate excretion 
(representing phosphate intake), 24-hour urinary urea excretion (representing protein 
intake), high-sensitivity C-reactive protein (hsCRP), serum albumin, hemoglobin, or NT-
proBNP levels, use of angiotensin-converting enzyme inhibitor or angiotensin receptor 
blocker, and use of vitamin D supplements. Variables significantly associated with 
FGF23 levels using backward linear regression analysis were subsequently tested in a 
forward linear regression model. Variables that were significant in this model were 
considered independent correlates of FGF23 levels.  
To assess whether mean FGF23 levels differed according to categories of EPA-
DHA intake or fish intake ANOVA models were used. EPA-DHA intake was divided into 
tertiles and fish intake was categorized as 0, >0–14, and ≥15 g/d (because of 18% no 
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fish eaters). Back transformation was performed to obtain geometric mean FGF23 
levels and 95% confidence intervals in categories of fish intake (or EPA-DHA intake). 
Several multivariable models were applied, adjusting for age and sex (model 1), and for 
lifestyle factors, i.e. total energy intake, alcohol use (0, >0-20, >20 g/d), smoking status 
and BMI (model 2). To identify potential dietary confounders, the association between 
main food groups (intake of bread, potatoes, vegetables, fruit, dairy and meat) and n-3 
fatty acid intake and FGF23 concentrations was tested (results presented in 
supplemental Table 1). P-values for the differences in dietary intake were obtained from 
the Kruskal-Wallis test for skewed variables. Based on the outcomes of this analysis, 
we additionally adjusted our data for fruit and vegetables intake (model 3) on the 
assumption that fish consumers are more likely than are fish non-consumers to follow a 
healthy diet rich in fruits and vegetables19. Finally, known determinants of FGF23, ie. 
serum calcium, phosphate and PTH were added to the full model (model 4).  
The association between fish or EPA-DHA intake and serum FGF23 was analyzed for 
an interaction by eGFR, either as a dichotomous or continuous variable, by adding an 
interaction term (eGFRxFGF23) to all ANOVA models. Because a significant interaction 
term was found (P<0.0001), we repeated the analyses in strata of renal graft function 






Patients were on average 53±13 years old and 57% was male. The mean BMI 
was 26.7± 4.8 kg/m2, with 59% of the patients being overweight. The median time since 
transplantation was 5.4 [1.9-12.2] years. Mean systolic blood pressure was 136/83 
mmHg and 91% of the cohort had hypertension. The mean fish intake was 15 g/d, 
which corresponds to approximately one serving per week, and EPA-DHA intake was 
139 mg/d. The median serum intact FGF23 level was 62 [IQR: 43-98] pg/mL. Patients 
with a reduced graft function (eGFR<60 mL/min/1.73m2, n=403, 65%) had a serum 
FGF23 concentration of 78 [IQR: 54-121] pg/mL, which was higher than in those with a 
normal graft function (n=216, 47 pg/mL [IQR: 35-61]; P<0.001). Patient characteristics 
in tertiles of EPA-DHA intake are shown in Table 1.  
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          Table 1. Characteristics of 619 renal transplant recipients across tertiles of EPA-DH 
 Tertiles of EPA-DHA intake (mg/d)  
  <39 (n=206) 40-158 (n=207)  ≥159 (n=206) P 
value 
Age (years) 51 ± 13  53 ±12 54 ± 12 0.03 
Sex, n (% males) 114 (55) 117 (56) 122 (59) 0.72 
BMI (kg/m2) 26 ± 5 26 ± 5 27 ± 4 0.31 
Waist circumference (cm) 98 ± 15 98 ± 15 100 ± 14 0.19 
Systolic BP (mmHg) 135 ±16 138 ± 17 135 ±18 0.27 
Diastolic BP (mmHg) 82 ±10 84 ±11 83 ± 11 0.18 
Time since transplantation (y) 6  [2-13] 6  [2-12] 6  [2-12] 0.80 
Current smoker n (%) 27 (14) 21 (11) 28 (14) 0.49 
Diabetes mellitus n (%) 40 (19) 31 (15) 42 (20) 0.21 
Alcohol use (g/d)     
     No 15 (8) 22 (12) 19 (11) 0.59 
     1-20 g/d 145 (78) 148 (78) 139 (77)  
     >20 g/d 27 (14) 19 (10) 23 (13)  
Energy (kcal)  2156 ± 672 2196 ± 601 2197 ± 641 0.42 
 
Medication use 
   
 
     Antihypertensives n (%) 183 (89) 181 (87) 180 (88) 0.90 
     Proliferation inhibitor n (%) 166 (81) 169 (82) 183 (89) 0.06 
     Mycophenolate n (%) 135 (66) 137 (66) 138 (67)  
     Azathioprine n (%) 31 (15) 32 (16) 45 (22)  
     Calcineurin inhibitor n (%) 120 (58) 127 (61) 104 (51) 0.08 
     Cyclosporine n (%) 80 (39) 81 (39) 89 (43)  
     Tacrolimus n (%) 40 (19) 41 (20) 32 (16)  
     Diuretics n (%) 86 (42) 82 (40) 84 (41) 0.91 
     Vitamin D supplements n (%) 45 (22) 52 (25) 45 (22)  0.68 
      
Serum parameters 
   
 
     Creatinine (µmol/L) 121 [95-159] 130 [102-164] 124 [103-153] 0.29 
     eGFR(ml/min/1.73 m2)* 55 ± 22 51 ± 20 52 ± 19 0.09 
     Urea (mmol/l) 9.3 [7.1-12.9] 9.5 [7.3-14.2] 9.8 [7.2-13.2] 0.42 
     PTH (pmol/l) 9.4 [5.6-14.7] 9.4 [6.3-14.5] 8.3 [5.5-13.4] 0.29 
     Albumin (g/l) 43 ± 3 43 ± 3 43 ± 3 0.98 
     hsCRP (mg/l) 1.4 [0.6-3.8] 1.6 [0.6-4.2] 1.7 [0.8-5.0] 0.61 
     Sodium (mmol/l) 141 ± 3 141 ± 3 141 ± 3 0.46 
     Potassium (mmol/l) 4.0 ± 0.4 4.0 ± 0.5 4.0 ± 0.5 0.92 
     Calcium (mmol/l) 2.4 ± 0.16 2.4 ± 0.15 2.4 ± 0.15 0.75 
     Phosphate (mmol/l) 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.7 0.52 
     Total cholesterol (mmol/L) 5.1 ± 1.2 5.1 ± 1.0 5.2 ± 1.1 0.84 
     HDL cholesterol (mmol/L) 1.4 ± 0.4 1.4 ± 0.5 1.4 ± 0.5 0.30 
     LDL cholesterol (mmol/L) 3.0 ± 0.9 2.9 ± 0.9 3.0 ± 1.0 0.71 
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Note: Values in table 1 are mean ± SD, n(%) or median (p25-p75). P values were obtained from 
ANOVA for normally distributed continuous variables, from Kruskall-Wallis test for skewed continuous 
variables and from Chi-squared test for categorical variables. EPA: eicosapentaenoic acid; DHA: 
docosahexaenoic acid; BP: blood pressure; *eGFR:  estimated glomerular filtration rate, based on 
Chronic Kidney Disease-Epidemiology (CKD-EPI) Collaboration formula; PTH: parathyroid hormone; 
hsCRP: high sensitivity C-reactive protein.  
 
Those who had a higher EPA-DHA intake were slightly older (P=0.03). No 
significant differences were observed in cardiovascular risk factors, medication use, or 
other clinical parameters. EPA-DHA intake was not associated with lipid profile (HDL, 
LDL, total cholesterol or triglycerides) or hsCRP. Multivariate regression analysis 
revealed independent determinants of FGF23 levels in our cohort (Table 2).  
 
Table 2. Multivariate analysis of FGF23 correlates 
 
Variable Standardized beta P value 
eGFR (CKD-EPI) -0.27 <0.001 
Serum phosphate 0.24 <0.001 
NTproBNP 0.24 <0.001 
Urinary phosphate excretion 0.17 <0.001 
Triglycerides 0.12 <0.001 
Age 0.10 0.01 
Gender (0=male; 1=female) -0.10 0.01 
Smoking (0=never; 1=ever) 0.08 0.01 
Parathyroid hormone 0.07 0.045 
Albuminuria 0.07 0.049 
Excluded from the model: use of RAAS blockers or vitamin D supplements, cold and warm ischemia times, 
time since transplantation, hemoglobin, donor status (living or deceased), presence of diabetes mellitus, 
BMI, urinary urea excretion, serum cholesterol, hsCRP. Model fit: R2 0.40.   
 
 
     Triglycerides (mmol/L) 1.9 ± 1.0  1.9 ± 1.0 1.8 ± 1.0 0.63 
 
Urinary parameters 
   
 
     Creatinine (µmol/24 h) 114 ± 36 115 ± 33 119 ± 31 0.32 
     Albumin (mg/24 h) 42 [9-184] 34 [9-172] 43 [11-152] 0.93 
     Sodium (mmol/24 h) 150 ± 58 157 ± 61 162 ± 63 0.11 
     Calcium (mmol/24 h) 2.4 [1.1-3.7] 2.3 [1.0-3.9] 2.3 [1.2-3.9] 0.88 




Fish consumption and circulating FGF23  
Circulating FGF23 levels were inversely related to fish intake (Table 3), with 
geometric mean levels of 78.0 pg/mL for 0 g/d, 73.3 pg/mL for 1-14 g/d and 64.4 pg/mL 
for ≥15 g/d (P-trend=0.06) after adjustment for age, sex, BMI and dietary and lifestyle 
factors (model 3). After adjustment for key determinants of FGF23 (serum calcium, 
phosphate and PTH), the association became statistically significant (P=0.03, Table 3, 
model 4). The association between fish intake and FGF23 levels was influenced by 
eGFR (P-interaction <0.0001 in all models). In patients with a reduced graft function 
(eGFR <60 mL/min/1.73 m2), FGF23 levels were 108.9 pg/mL, 89.5 pg/mL and 77.0 
pg/mL (P=0.003) in consecutive categories of fish intake, using the fully adjusted model. 
The association was not significant in those with normal graft function (P>0.2, Table 3).  
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Table 3.  Fish intake and serum FGF23 levels (pg/mL)a in 619 renal transplant patients, in the total 
cohort and stratiﬁed by renal graft function. 
    Fish intake (g/d)   
      
     0              1-14     15         P-value 
Total cohort       
N 108  234  277  
Model 1 72.3 (63.0-82.9) 72.0 (65.6-79.0) 64.5 (59.2-70.2) 0.167 
Model 2 76.7 (66.3-88.8) 73.5 (66.4-81.4) 64.2 (58.5-70.5) 0.063 
Model 3 76.9 (66.4-89.0) 73.4 (66.2-81.4) 64.3 (58.4-70.6) 0.067 
Model 4* 76.7 (68.1-86.4) 75.5 (69.4-82.1) 62.8 (58.1-67.8) 0.002 
Patients with eGFR <60 mL/min/1.73 m2.     
N  62  
             
149       192  
Model 1 99.5 (82.5-120.0) 91.4 (81.0-103.1) 75.8 (68.1-84.3) 0.015 
Model 2 
106.
7 (87.3-130.4) 93.1 (81.4-106.4) 75.2 (67.1-84.4) 0.005 
Model 3 
107.
6 (88.0-131.6) 92.2 (80.5-105.6) 75.3 (67.1-84.6) 0.005 
Model 4 
107.
3 (89.7-128.3) 89.6 (79.4-101.2) 77.0 (69.5-85.3) 0.005 
Patients with eGFR _60 mL/min/1.73 m2.     
N    46  85  85  
Model 1 46.1 (40.4-52.5) 47.4 (43.1-52.1) 45.2 (41.1-49.7) 0.784 
Model 2 49.1 (42.9-56.2) 48.8 (44.1-53.9) 42.2 (37.9-47.0) 0.104 
Model 3 48.7 (42.5-55.7) 49.3 (44.6-54.5) 42.2 (37.9-47.0) 0.091 
Model 4 48.1 (42.4-54.5) 49.5 (45.1-54.4) 42.3 (38.3-46.8) 0.071 
 
a FGF23 levels are geometric means (95% conﬁdence interval).Model 1 Z age and gender adjusted;  
Model 2 Z model 1 þ energy intake, alcohol consumption, smoking status, BMI and use of vitamin D 
analogues;  Model 3 Z model 2 þ vegetables and fruit;  Model 4 Z model 3 þ serum calcium, phosphate 
and PTH;  Model 4* Z model 3 þ eGFR,  serum calcium, phosphate and PTH.  
 
EPA-DHA intake and circulation FGF23 
 
Circulating FGF23 levels decreased with increasing EPA-DHA intake (Table 4), 
with geometric mean levels of 81.9 pg/mL for <39 mg/d, 63.9 pg/mL for 40-158 mg/d 
and 65.6 pg/mL for ≥159 mg/d (P=0.003) after adjustment for age, sex, BMI and dietary 
and lifestyle factors (model 3). After further adjustment for key determinants of FGF23, 
this inverse association remained (P=0.001, Table 4).  
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Table 4. EPA-DHA intake and serum FGF23 levels (pg/mL)# in 619 renal transplant patients, in the total 
cohort and stratified by renal graft function 
 
 EPA-DHA intake (mg/d)  
 
        <39       40-158          ≥159 
 
P-value 
Total cohort     
N 206         207           206  
Model 1 76.9 (69.6-84.9) 64.9 (58.8-71.6)  64.7 (58.6-71.4)    0.022 
Model 2 81.2 (72.9-90.4) 64.1 (57.6-71.2)  63.3 (58.6-72.9)    0.004 
Model 3 81.3 (72.9-90.5) 64.1 (57.6-71.4)  65.3 (58.4-72.9)    0.004 
Model 4* 86.5 (79.3-94.3) 62.1 (57.0-67.6)  63.4 (58.0-69.3)   <0.0001 
 
Patients with eGFR <60 ml/min/1.73 m2 
  N  116 141 146  
Model 1       106.4 (92.9-121.9)     80.0 (70.8-90.4)  74.6 (66.2-84.2) 0.0004 
Model 2       113.1 (97.4-131.2)     78.6 (68.9-89.7)  75.4 (66.1-86.1) 0.0001 
Model 3      112.7 (97.0-131.0)     78.7 (69.0-89.8)  75.3 (65.9-86.0) 0.0002 
Model 4      108.3 (94.7-123.8)     78.0 (69.3-87.8)  78.4 (69.6-88.0)  0.0003 
 
Patients with eGFR ≥60 ml/min/1.73 m2 
          N 90    66    60  
Model 1     50.3 (45.9-55.2)       41.6 (37.4-46.3) 45.7 (40.9-51.1) 0.030 
Model 2    53.0 (48.3-58.2)      40.2 (36.0-44.8) 44.0 (38.9-49.7) 0.001 
Model 3    52.7 (48.0-58.0)      40.0 (35.8-44.8) 44.9 (39.6-50.9) 0.001 
Model 4    52.7 (48.2-57.5)      41.3 (37.2-45.9) 43.3 (38.5-48.7) 0.001 
 
#FGF23 levels are geometric means (95% confidence interval) 
 Model 1=age and gender adjusted                                                                                                                                          
 Model 2=model 1 + energy intake, alcohol consumption, smoking status,  BMI and use of vitamin D suppplements  
 Model 3=model 2 + vegetables and fruit                                                                                                                       
 Model 4=model 3 + serum calcium, phosphate and PTH                                                                                                            
 Model 4*=model 3+ eGFR, serum calcium, phosphate and PTH 
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As for fish intake, the association between EPA-DHA intake and FGF23 was 
influenced by eGFR (P-interaction <0.0001 in all models). In patients with a reduced 
graft function (eGFR <60 mL/min/1.73 m2), FGF23 levels were 109.6 pg/mL, 77.9 pg/mL 
and 78.2 pg/mL (P-trend=0.0002) in consecutive tertiles of EPA-DHA, using the fully 
adjusted model 4 (Figure 1).  
 
Figure 1. Serum FGF23 levels (pg/mL) according to tertiles of dietary EPA-DHA intake stratified by renal 
graft function (eGFR above or below 60 ml/min/1.73m2).  
 
In those with an eGFR >60 mL/min/1.73 m2, the association with EPA-DHA 
intake was also significant (P=0.004), but FGF23 levels were 50% lower than in those 
with reduced graft function (Table 4). Further adjustments for urinary sodium and 





The main finding of the current study is the inverse association of fish and dietary 
intake of n-3 long-chain polyunsaturated fatty acids (EPA-DHA) with serum FGF23 
levels in a large cohort of renal transplant recipients. Particularly in patients with 
reduced graft function (eGFR <60 mL/min/1.73m2) circulating FGF23 levels were 
reduced with increasing tertiles of EPA-DHA or categories of fish intake.  
Daily intake of fish (~15 g/d) and EPA-DHA (~139 mg/d) in our cohort of renal 
transplant recipients was well below the recommended intake levels of two servings of 
fish per week, equaling 450 mg/d EPA-DHA20. Similar low levels of intake (15 g/d fish) 
were also observed in a recent clinical trial in post-myocardial infarction patients in The 
Netherlands21. A strong point of the present study is the large, well-characterized cohort 
of renal transplant recipients, with extensive dietary data collection, serum samples and 
24-hour urinary samples. This enabled us to adjust for many potential dietary 
confounders, including 24-hour sodium and phosphate excretion. Nevertheless, since 
this is an observational study, we cannot exclude the possibility of residual confounding 
by (unmeasured) dietary or lifestyle factors, such as physical activity, that could 
potentially have influenced serum FGF23 in our patients. Furthermore, we did not 
measure a circulating biomarker of n-3 fatty acid content to confirm the association 
between n-3 fatty acid intake and FGF23 levels. Another limitation is the cross-sectional 
nature of our study, and patients may have intentionally changed their diets for health-
related reasons. On the other hand, since fish is not a major contributor to total daily 
protein and mineral intakes, we consider it unlikely that patients have been advised to 
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change their intake of fish. Finally, we did not adjust for serum vitamin D levels or 
dietary vitamin D intake as such parameters were lacking in the present cohort.  
Pharmacological supplementation of vitamin D did however not contribute to 
FGF23 levels, nor did it influence the association between EPA-DHA intake and FGF23 
levels. Although our data do not allow us to draw conclusions on how fish or EPA-DHA 
could regulate FGF23 levels, we can speculate on a potential mechanism through anti-
inflammatory effects increasing renal klotho expression. Pro-inflammatory cytokines 
have been linked to a reversible klotho down-regulation in the kidney22. In line, FGF23 
levels have recently been linked with systemic inflammation in CKD23. The inverse 
association between EPA-DHA intake and FGF23 could therefore be explained by a 
partial restoration of renal klotho expression due to its anti-inflammatory effects on 
tubular epithelial cells24. Also, n-3 fatty acids may increase the expression of antioxidant 
genes25, and oxidative stress has been associated with lower klotho expression26. Of 
interest, interventions that reduced oxidative stress partially restored renal klotho 
expression in animal models27. As an alternative explanation, n-3 fatty acids could act 
directly on the PTH receptor, a potent inducer of FGF2328; yet adjustment for 
phosphate, calcium and PTH did not change the observed association between n-3 fatty 
acid or fish intake and FGF23. 
Serum FGF23 levels have been shown to be influenced by phosphate-rich foods, 
particularly by protein from animal sources. Yet the most important factor contributing to 
FGF23 levels is suggested to be inorganic phosphate29. 
In summary, the present study showed for the first time that fish and EPA-DHA 
intake are associated with serum FGF23 levels in a large cohort of renal transplant 
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recipients. Future prospective studies should address whether increased fish or EPA-
DHA intake could be new strategies to reduce cardiovascular morbidity and mortality 
after kidney transplantation through reduction of FGF23. 
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Introduction: Renal inflammation importantly contributes to progressive renal function 
loss. Klotho is an anti-aging factor with renoprotective properties which is expressed in 
the kidney. Renal inflammation promotes loss of klotho expression, and conversely, 
restoring renal klotho expression may be a target for intervention. Given the well-
established anti-inflammatory effects of n-3 fatty acids in different disease conditions, 
we aimed to investigate the effect of fish oil supplementation in an experimental model 
of renal inflammation.  
Methods: Male C57BL/6 mice were fed an adenine-enriched diet (ADN) to induce 
inflammatory renal damage, or standard chow (CON) for 10 days, and were 
subsequently randomized to receive either fish oil [standard diet + 6.3% of fish oil and 
0.7% of soybean oil] or soybean oil [standard diet + 7% of soybean oil] for 15 days in a 
2x2 design.  
Results: ADN+soybean oil animals developed impaired renal function, reduced renal 
klotho expression, increased renal expression of pro-inflammatory cytokines heme 
oxygenase-1 and IL-6, and increased collagen deposition compared with CON+soybean 
oil (all P<0.05). Conversely, treatment of ADN mice with fish oil prevented 
downregulation of renal klotho expression, abolished renal inflammation, decreased 
collagen deposition and restored renal function (all P<0.05 vs ADN+soybean oil). 
Conclusions: A fish oil enriched-diet effectively prevented renal klotho loss, intra-renal 
inflammation and collagen deposition, and restored renal function in a model of 
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inflammatory renal damage. Fish oil-based dietary intervention may provide 




Chronic kidney disease (CKD) is a global health problem, accompanied by a high 
rate of cardiovascular complications, premature mortality and an excessive financial 
burden. Current standard renoprotective therapies, mostly consisting of renin-
angiotensin-aldosterone system (RAAS)-blockade and reduction of volume overload, 
are insufficiently effective to prevent CKD progression in many patients.  
The transmembrane protein klotho has recently been identified as an 
endogenous inhibitor of aging-related processes including vascular calcification1, renal 
fibrosis, and a reduced life span2-3. Under healthy conditions, klotho is highly expressed 
in renal tubules, where it serves as a co-factor for the fibroblast growth factor 23 
(FGF23) receptor4-5. The hormone FGF23 is a key factor involved in the regulation of 
phosphate metabolism, by stimulating phosphaturia and suppressing vitamin D 
activation.  
In CKD, renal Klotho expression is progressively lost, which is accompanied by 
strongly increased FGF23 levels and RAAS activation6. Decreased expression of Klotho 
mRNA and protein has been confirmed in humans with CKD7 and both renal Klotho loss 
and high FGF23 levels have been associated with adverse cardiorenal outcomes in 
CKD patients in different stages of disease severity8. Moreover, in experimental CKD 
models, treatment with recombinant Klotho protected against renal damage9 as well as 
uremic cardiotoxicity10-11. Furthermore, upregulation of endogenous renal klotho by 
RAAS-blockade12 or vitamin D receptor activator treatment13 is accompanied by 
cardiorenal protection in CKD. Thus, interventions restoring renal klotho expression may 
be beneficial adjunct therapies to improve cardiorenal outcome in CKD.  
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Pathophysiologically, klotho deficiency may contribute to renal function loss by 
promoting renal inflammation14. Vice versa, inflammatory cytokines may downregulate 
renal klotho expression15. Thus, treatment strategies targeting renal inflammation may 
be able to restore klotho and reduce renal damage.  
Omega-3 fatty acids such as docosahexaenoic (DHA) and eicosapentaenoic 
(EPA) exert anti-inflammatory effects and may have renoprotective effects in CKD, as 
shown in animal16 and clinical17 studies. Moreover, we recently found that higher intake 
of EPA-DHA was independently associated with lower levels of FGF23 in renal 
transplant recipients18, supporting the potential of omega-3 fatty acids to favorably affect 
the FGF23-klotho axis. In this study we prospectively investigated whether a diet rich in 
EPA-DHA could increase renal klotho expression and reduce renal inflammation and 






C57/Bl6 wild-type mice, aged 8 to 12 weeks, were obtained from the Center for 
Development of Experimental Medicine and Biology (CEDEME) of the Federal 
University of Sao Paulo (UNIFESP) and acclimatized for 8 days prior to the initiation of 
the study. The animal room was maintained at the temperature of 22 ± 2ºC and 50 - 
60% relative humidity with 12h light/dark cycles. The animals were fed with standard 
pellet diet and had ad libitum access to water19.   
Renal inflammation was induced by adenine administration20. First, animals were 
divided into two groups (n=14 per group): one group of animals was fed with 0.25% 
adenine enriched food (Rhoster, Aracoiaba da Serra, Brazil) for 10 days, and another 
group received standard chow. From the 11th day on, all animals were fed with a 
standard diet with addition of either soybean oil or fish oil, according to each respective 
group, for 15 days. The animals were further divided into four groups (Figure 1): 
Control-Soybean oil [standard diet + 7% of soybean oil]; Control-Fish oil [standard 
diet + 6.3% of fish oil and 0.7% of soybean oil]; Adenine-Soybean oil [standard diet 
added of adenine + 7% of soybean oil]; Adenine-Fish oil [standard diet added of 








The n-3 fatty acids were added to the diet as fish oil given its high DHA and EPA 
content. All oil-enriched diets were purchased from PragSoluções (Jau, Sao Paulo, 
Brazil) and were in accordance with the American Institute of Nutrition’s 
recommendation (AIN 93G). The diets were matched for energy content. Food intake 
and body weight were assessed weekly. All of the procedures were examined and 
approved by the Animal Ethics Committee of the Federal University of Sao Paulo, 
Brazil, (CEUA-UNIFESP, 1558280214). 
At the end of the study, the animals were anesthetized with xylazine (10 mg/kg) 
and ketamine (50 mg/kg) by intra-peritoneal injection. Blood samples were collected at 
the end of the study. The animals were sacrificed by cardiac puncture and 
exsanguinated. The kidneys were harvested and immediately dissected and washed 
with saline. All kidneys were embedded in paraffin, sectioned longitudinally and 
processed routinely for histologic examination. The remaining part was snap frozen in 
liquid nitrogen and stored at -80ºC. Serum creatinine was measured by the Jaffe 
modified method, and serum urea was measured using a Labtest Kit (Minas Gerais, 
Brazil) according to the manufacturer’s instructions.  
 
Realtime PCR 
Renal heme oxygenase-1 (HMOX), IL-6, TGF-β and klotho gene expressions 
were determinated by realtime RT-PCR. Renal tissues were crushed, homogenized and 
the RNeasy Mini Purification Kit (Qiagen) was used to extract RNA from all samples. 
RNA quantification was carried out using a NanoDrop Spectrophotometer (NanoDrop 
ND-1000 Spectrophotometer; Thermo Scientific, Wilmington, DE). Nucleic acid 
130 
 
concentration was determined using ultraviolet spectrophotometry at 260 nm and purity 
was determined using the absorbance ratios of 260/280 and 260/230. RNA was reverse 
transcribed using the QuantiTec SYBR Green Kit (Qiagen) and the manufacturer’s 
instructions were followed. Reverse transcription and Real-Time PCR were performed 
using commercially available reagentsand a 7500 Fast Real-Time Thermocycler 
(Applied Biosystems). For relative quantification of message expression (ΔΔCT 
Method), target gene expression was normalized to HPRT gene expression.  
The following mice primers were used for quantitative RT-PCR measurements: 
KLOTHO fw: GGTGTCCATTGCCCTAAGCTC; KLOTHO rev: 
TCGGTCATTCTTCGAGGATTGA; HPRT fw: CTCATGGACTGATTATGGA-CAGGAC; 
HPRT rev: GCAGGTCAGCAAAGAACT TATAGCC; HMOX1: Mm00516004_m1; IL6: 
Mm00446190_m1; TGFβ: 1Mm01178820_m1. 
 
Histological evaluation 
Formaldehyde-fixed paraffin kidney sections (3 m) were dewaxed and stained 
with Picrosirius solution. Sections were immersed in saturated picric acid solution for 15 
minutes and then in Picrosirius for 20 more minutes. Counter-staining was carried out 
with Harris hematoxylin. Picrosirius stained sections were analyzed by an Olympus 
BX50 microscope with an Olympus camera attached. Manual shots were taken of the 
cortex, magnified 40X, and observed under polarized light. Photos of at least 5 different 
fields in each slide were taken, and structures such as the glomeruli, subcapsular 
cortex, large vessels and medulla were excluded. The pictures were digitalized (HP 
Scanjet 2400) and then the interstitial volume of collagen in the cortex compared to the 
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overall cortex area was quantified by morphometry. For the morphometric analysis, the 
Image Processing and Analysis in Java (Image J) software was used. The result of the 
analysis is represented as a percentage of cortical interstitial collagen volume relative to 
the total cortical interstitial volume. Subsequently, the arithmetic mean of the analyzed 
fields was calculated for each slide. Assessment of the interstitial fibrosis volume 
obtained by morphometric analysis of the digital image stained with Picrosirius was 
based on previous studies21. 
 
Statistical analyses 
Variables are presented as median (interquartile range) unless indicated 
otherwise. Differences between groups were assessed using non-parametrical Mann 
Whitney tests. All statistical analyses were performed using SPSS software, version 
16.0 for Windows (IBM, Armonk, NY). P values <0.05 were considered to represent 










Body weight and renal function 
Body weight increased in the adenine groups treated with soy oil  by 2.1±0.7g 
from the start of treatment to sacrifice, and tended to increase also in the adenine group 
treated with fish oil group (0.6±1.1g). In the control groups, body weight remained stable 
(Control+soy oil: -0.2±0.6 g and Control+fish oil 0.1±1.8 g). The effect of each treatment 
on renal function parameters is shown in Figure 2.  
 
 
 Figure 2. (A)Serum creatinine; (B) Serum urea levels 
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Adenine-treated animals that received soybean oil developed renal function 
impairment, as reflected by an increased serum creatinine (0.72±0.06 mg/dl) and urea 
(147.2±46.9 mg/dl) compared with control mice on soybean oil (creatinine: 0.49±0.08 
mg/dl; urea 57.5±13.2 mg/dl, both P<0.05 vs adenine+soybean oil). Interestingly, 
treatment of adenine mice with fish oil completely prevented the increase of serum 
creatinine (0.54±0.11 mg/dl) and urea (78.1±32.1 mg/dl, both P<0.05 vs 
adenine+soybean oil).  
 
Renal klotho and -inflammatory response  
In parallel with the observed decrease in renal function, renal klotho gene expression 
was strongly reduced in the adenine+soybean oil group, as compared to the respective 
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Figure 3. Renal klotho expression. Adenine-treated mice on soybean oil presented 
reduced renal klotho expression compared to its respective control group and the fish 





Treatment of adenine mice with fish oil preserved renal klotho expression 
(P=0.04). In the control groups, fish oil treatment did not affect klotho expression.  
Renal expression of HMOX and IL-6 were strongly increased in the adenine mice 
receiving soybean oil compared to control mice (both P<0.05), whereas fish oil 
treatment abolished the rise in these renal inflammation markers (P<0.05 vs adenine + 




Renal (pro-)fibrotic changes  
Similar to the effects on inflammation parameters, renal TGF-β gene expression 
was significantly higher in adenine + soybean oil group compared to the control group 
(P=0.01). Fish oil treatment strongly reduced renal TGF-β gene expression in adenine-
treated mice, compared to the adenine+soybean oil group (P=0.05; Figure 5).  




























































Figure 5. Renal expression of TGF-β. 
 
Tubular collagen deposition was higher in the adenine group receiving soybean 
oil as compared with the control group. (P=0.05; Figure 6). Collagen deposition was 
significantly reduced in adenine mice that received fish oil compared to adenine + 




















































We report for the first time that inflammation-induced renal klotho downregulation 
in mice can be reversed by a fish oil-enriched diet. Restoration of renal klotho 
expression was accompanied by reduced renal inflammation and collagen deposition in 
response to fish oil treatment and amelioration of renal function impairment. 
The adenine-enriched food utilized in the present study, provides an excess of 
this purine, which in turn is a substrate for xanthine dehydrogenase conversion to 
adenine to 2,8-dihydroxyadenine, an insoluble compound that precipitates in the tubule-
interstitial compartment, causing nephrolithiasis followed by extensive tubular dilation, 
necrosis and apoptosis22. The presence of damaged tissue then initiates an intense 
inflammatory process, which apparently contributes to the progression of the tubulo-
interstitial nephritis (TIN). 
The higher renal expression of  IL-6 and TGF-β observed in the adenine group 
treated with soybean oil substantiates that indeed intra-renal inflammation and fibrosis 
were  present in our model,as previously described23-24,  leading to decreased renal 
klotho expression. HOX-1 enzyme, encoded by the HMOX gene, possesses a dual 
effect depending on the timing of the renal insult25. Whereas its up-regulation may be 
protective because of its antioxidant, antiapoptotic, anti-inflammatory and 
immunomodulatory properties, it also increases in response to oxidative stress, 
cytokines and hypoxia, acting like a heat shock protein (HSP). Therefore, its increase in 
the present study further reinforces the presence of tissue inflammation. Treatment of 
adenine animals with fish oil, conversely, reduced renal inflammation-related genes and 
completely restored renal klotho levels. Moreno et al15 have previously shown that 
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proinflammatory cytokines such as TNF and TNF-like weak inducer of apoptosis 
(TWEAK) induce Klotho downregulation in a dose-dependent fashion in cultured renal 
cells, that TWEAK decreases kidney Klotho in vivo, and that targeting TWEAK prevents 
Klotho downregulation during acute kidney injury induced by folic acid in mice.  
During the inflammation process, several cytokines and lipid-derived mediators 
(prostaglandins, leukotrienes and endocanabinoids) are secreted, mostly by leukocytes 
attracted to the site of inflammation by locally released chemo-attractants26 It is 
important to note that the pro-inflammatory lipid-derived mediators are, mostly, 
synthetized from the n-6 fatty acid arachidonic acid (ARA), by the enzyme delta-6 
desaturase.  Through important inflammatory pathways such as cyclo-oxygenase 
(COX), cytochrome P450 (CYT p450) and lipoxygenase (LOX), different series of 
leukotrienes, prostagrandins, lipoxins and tromboxanes are generated from ARA26. The 
linolenic acid, an n-3 fatty acid, is the preferable substrate for the delta-6 desaturase 
enzyme instead of linoleic acid27. The end-products produced from  the linolenic acid 
are EPA and DHA, which are reported to have very potent anti-inflammatory 
properties28. Besides, EPA and DHA can be ingested through n-3 fatty acid-rich foods 
consumption, such as flesh of oily fish (e.g. salmon) and also liver of lean fish (e.g. cod 
liver)29. 
Upon induction of inflammation by adenine administration as shown in our model, 
the aforementioned pro-inflammatory pathways may be activated and the substrate 
present in predominant amounts will then be used. Considering that in normal 
conditions, ARA is the most available substrate, the end-products will be the ARA-
derived mediators which are highly pro-inflammatory. Inclusion of EPA, DHA, or both in 
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the diet fed to mice results in increased amounts of these fatty acids in phospholipids 
membranes of lymphocytes, macrophages and neutrophils30-31; this might lead to 
increased production of EPA- and DHA-derived mediators. Besides, the beneficial anti-
inflammatory effects of n-3 fatty acids supplementation have been reported in different 
disease conditions32. N-3 fatty acids such as EPA and DHA may also be used as 
substrate in the COX, LOX and CYTp450 pathways generating eicosanoids and 
bioactives named resolvins, respectively. The eicosanoids synthetized from EPA have 
different structures compared to the ARA-derived mediators and are less biologically 
active since the EPA-derived eicosanoids have less affinity with the eicosanoids 
receptors. Therefore, the eicosanoids produced from EPA are considered far less 
potent than the ones produced from ARA leading to a reduced inflammatory 
response26,33 . 
Given the negative feedback loop between inflammation and klotho expression14-
15, reducing inflammation may retrieve klotho expression as demonstrated previously15. 
In turn, klotho loss may directly promote renal fibrosis, for example through FGF2 
activation34. This is in line with the current study, where we found lower klotho 
expression accompanied by higher tubular collagen deposition in the adenine-soy oil 
group compared to controls, which was reversed by treatment with fish oil. 
It is important to note that the present study has some limitations. First, our study does 
not allow to draw conclusions on cause-effect relationships between renal klotho 
expression and pro-inflammatory and pro-fibrotic renal damage. On the other hand, the 
effects of fish oil supplementation on both renal klotho and parameters of renal damage 
were quite strong, and fish oil was even able to prevent renal function loss in our study. 
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This provides a rationale to further explore the potential of fish oil in patients with, 
preferably inflammation-driven, chronic kidney disease. We provided a relatively high 
dose of fish oil to the animals; dose-response studies are required to detect which 
amounts of fish oil would be needed to provide optimal renoprotection.  
In conclusion, a fish oil enriched-diet effectively prevented renal klotho loss by 
reducing intra-renal inflammation, and these beneficial effects resulted in clear anti-
fibrotic effects and restored renal function. The present study reveals a renoprotective 
effect of fish oil supplementation in inflammation-driven CKD and provides a rationale to 
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Background and objectives: Fibroblast growth factor 23 (FGF23) is an independent 
risk factor for cardiovascular mortality in chronic kidney disease. In an earlier study we 
found an inverse association of intake of the marine N-3 fatty acids eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA)  with circulating levels of FGF23 in 
patients with impaired renal function. In the current study, we aimed to examine the 
effect of these marine N-3 fatty acids and of plant-derived alpha-linolenic acid (ALA) on 
plasma FGF23 levels in post-myocardial infarction patients with impaired renal function. 
Design, setting, participants and measurements: In the randomized double-blind 
Alpha Omega Trial, 4837 patients with history of myocardial infarction aged 60-80 years 
(81% men) were randomized to one of four trial margarines supplemented with a 
targeted additional intake of 400 mg/d EPA and DHA, 2 g/d ALA, EPA-DHA plus ALA, 
or placebo for 40 months. In a subcohort of patients with cystatin C-based eGFR <60 
ml/min/1.73 m2 (n=352), plasma C-terminal FGF23 was measured by ELISA at baseline 
and follow-up. We used analysis of covariance to examine treatment effects on 
(loge)FGF23 levels adjusted for baseline FGF23.  
Results: On average 19.8 g margarine/d was consumed, proving an additional amount 
of 236 mg/d EPA with 158 mg/d DHA, 1.99 g/d ALA or both, in the active treatment 
groups. At baseline, geometric plasma mean FGF23 level was 117 (95%CI 110 to 124) 
RU/ml. After 40 months, overall geometric mean FGF23 levels had increased to 150 
(140 to 162) RU/ml. Compared with the placebo group (n=79), the treatment effect was 
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indifferent for all active treatment groups: EPA-DHA (-6% (95% CI -23% to -11%), 
n=82), ALA (+5% (-12% to 21%), n=96), or EPA-DHA plus ALA (+8% (-9% to 24%), 
n=95) groups. Multivariate adjustment, pooled analyses, and subgroup analyses yielded 
similar results. 
Conclusion: Long-term supplementation with modest quantities of EPA-DHA, whether 
or not in combination with ALA, did not affect plasma FGF23 levels in post-myocardial 




Patients with chronic kidney disease (CKD) are at increased risk of 
cardiovascular disease. The prevalence of ischemic heart disease, left ventricular 
hypertrophy and heart failure increases with declining renal function, resulting in an 
increased risk of cardiovascular mortality that is up to 10-30 times higher in 
hemodialysis patients than in the general population1. Although several classical 
cardiovascular risk factors such as diabetes and hypertension are more prevalent in 
CKD than in the general population, these factors do not explain all of the excessive 
cardiovascular risk in these patients2-3.  
Derangement of metabolic pathways, including calcium/phosphate homeostasis, 
are likely to contribute to the premature development and rapid progression of 
cardiovascular disease in CKD patients. Recent epidemiological studies have linked a 
high plasma level of the phosphaturic hormone fibroblast growth factor 23 (FGF203) 
with an increased risk of cardiovascular morbidity and mortality in CKD patients4-7. A 
higher FGF23 level has also been associated with a poorer response to intensified 
renin-angiotensin-aldosterone system (RAAS)-blockade-based therapy, one of the key 
components of preventive therapy in patients with both renal and cardiovascular 
disease8. FGF23 promotes urinary excretion of phosphate, and its plasma 
concentrations increase in parallel with the stages of CKD9. Particularly in CKD patients 
with a history of cardiovascular disease, plasma FGF23 is associated with an increased 
mortality risk10.  
In order to explore whether FGF23 reduction could provide cardiovascular 
protection in CKD patients, novel strategies to lower plasma FGF23 levels are needed. 
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We recently found in a cohort of renal transplant recipients, that n-3 fatty acid 
intake was inversely associated with FG23 levels, independent of known determinants 
of FGF23 levels11. Furthermore, supplementation with n-3 fatty acids provided a small 
beneficial effect on renal function in patients with a history of myocardial infarction 
(Alpha Omega Trial)12, which may in turn lead to a reduced plasma FGF23 level. These 
observations may be reconciled with a prospective study showing cardiovascular 
protective effects of n-3 fatty acids in the CKD population13. On the other hand, an 
open-label controlled trial in 47 hemodialysis patients with relatively short follow-up (6 
months) was unable to demonstrate an effect of n-3 supplementation on plasma FGF23 
levels14.  
We addressed whether intervention with dietary n-3 fatty acid supplementation 
during 40 months reduces plasma FGF23 levels in post-myocardial infarction patients 
with impaired renal function (eGFR <60 ml/min/1.73 m2), as a post-hoc analysis of the 




Design of the Alpha Omega Trial 
The present study used data from the Alpha Omega Trial, a multicenter, 
randomized, double-blind, placebo-controlled trial conducted between 2002 and 2009 
(ClinicalTrials.gov no. NCT00127452). Details of the trial have been reported 
previously15-16. In brief, the study population consisted of 4837 patients with a history of 
myocardial infarction living in The Netherlands, who were 60–80 years old upon 
inclusion, and received state-of-the-art antihypertensive, antithrombotic, and lipid-
modifying drug treatment. Patients were recruited sequentially and randomly assigned 
to receive one of four trial margarines (20 g daily) for 40 months. The trial margarines 
were identical except for their n-3 fatty acid content, and provided a targeted additional 
daily intake of 400 mg eicosapentaenoic acid (EPA)-docosahexaenoic acid (DHA) (ratio 
of 3:2), a targeted additional daily intake of 2 g α-linoleic acid (ALA), a combination of 
EPA-DHA and ALA, or placebo. Patients were asked to refrain from n-3 fatty acid 
supplements during participation in the trial. Compliance to the trial margarines was 
monitored by counting of margarine tubs, telephone interviews, and patient diaries. The 
present study was limited to patients randomized before August 2005 (Figure 1).  
For the present study, patients with impaired renal function, defined as an 
estimated GFR <60 ml/min/1.73 m2 were selected. The eGFR was calculated using the 
cystatin C-based CKD-EPI formula17. Blood samples were drawn at baseline and after 
40 months of follow-up. The Alpha Omega Trial was conducted in accordance with the 
Declaration of Helsinki and approved by a central medical ethics committee in The 
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Netherlands (Office for Human Research Protections #IORG000404). Written informed 
consent was obtained from all patients. 
 
Laboratory measurements 
Standardized blood handling procedures were previously described in detail18. 
Briefly, nonfasting blood samples were obtained at the participant’s home or hospital. 
Subsequently, tubes were packaged in sealed envelopes and sent by standard postal 
service to a central laboratory.  
At baseline and at 40 months of follow-up, cystatin C was measured from stored 
blood samples in a central laboratory. Serum cystatin C was measured using a particle-
enhanced immunonephelometric assay (N Latex Cystatin C, Dimension Vista 1500 
Analyzer; Siemens), as described previously12. Calibrators and assays of the same lot 
code were used, which was stable. Cystatin C was calibrated directly using the standard 
supplied by the manufacturer19. The analytical measurement range of cystatin C was 
0.23–8.00 mg/L. Intra- and interassay variation coefficients for low cystatin C (1.00 
mg/L) were 1.3% and 4.2%, respectively. These variation coefficients for high cystatin C 
(1.75 mg/L) were 2.9% and 2.8%, respectively. Intra- and interassay variations were 
0.8% and 2.2%, respectively.  
Plasma C-terminal FGF23 levels were determined at baseline and at 40 months 
of follow-up by sandwich ELISA (Immutopics, San Clemente, CA), with intra-assay and 




Demographic and clinical data collection 
Patients were interviewed and physically examined by trained research nurses at 
home or in the hospital at baseline and after 40 months. Information on demographic 
variables, lifestyle habits, current health status, and medical history was collected by 
self-administered questionnaires as previously described in detail16. Ethnicity was 
categorized as white, black, or other. Medication was coded according to the 
Anatomical Therapeutic Chemical Classification System. Diabetes was defined as self-
reported physician diagnosis, antidiabetic medication (including insulin) or by casual 
plasma glucose concentrations (≥7 mmol/l (126 mg/dl) for those fasting and ≥11.1 
mmol/l (200 mg/dl) for non-fasting patients)21. 
  
Statistical analyses 
A pre-specified statistical analysis plan was used for these analyses. Baseline 
descriptives in the four treatment groups were presented as mean ± SD, median with 
interquartile range (IQR) or percentage. Intention-to-treat analyses were performed. 
Since plasma FGF23 concentrations were positively skewed, baseline and 40-month 
values were loge-transformed before analyses to obtain normal distributions. Back-
transformed geometric means and 95% confidence intervals are presented. The plasma 
FGF23 concentration at 40 months of treatment, adjusted for the baseline FGF23 level, 
was analyzed using Analysis of covariance (ANCOVA) models with treatment as 
independent variable based on a previous publication22. The P-value for equal error 
variances (Levene’s test if >0.05) indicates whether the error variance is equal across 
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the treatment group, i.e. whether the assumption of equal error variances is met and 
ANCOVA is the correct method for comparing the groups. The primary objective was to 
compare FGF23 concentrations at the end of follow-up between the EPA-DHA group 
vs. the placebo group. As secondary analyses, we studied the effects of ALA vs. 
placebo and the combination of EPA-DHA and ALA vs. placebo on plasma 
concentrations of FGF23. Adjustments for several covariates (age, sex, plasma 
phosphate, cigarette smoking, alcohol intake, education level, prevalent diabetes, 
physical activity status and CRP levels) were performed. Spearman correlation 
coefficients were calculated for the relationship between eGFR and FGF23. Subgroup 
analyses were performed according to the presence of diabetes mellitus, obesity, or 
both at baseline, after exclusion of subjects with extreme FGF23 values at baseline. As 
a secondary analysis we analyzed the intervention groups according to the 2*2 factorial 
design as in the original paper15, retaining statistical power by keeping all treatments 
groups in the analyses and less between-treatment comparisons then the initially used 
method. All analyses were performed blind to the intervention code. Statistical analysis 
was carried out using SPSS vs 20.0 (SPSS, Inc., Chicago, IL). Two-sided p values < 





Characteristics of the study population 
Our study population consisted of 352 patients with a mean age of 73.0 years 
(SD 4.9), 68.5% were males, 28.8% had obesity, 26.7% had type 2 diabetes and 16.2% 
were current cigarette smokers. The median period between the index myocardial 
infarction and entry into the study was 3.9 years (interquartile range, 1.9 to 6.2). Statins 
were used by 79.0%, 93.8% used blood pressure lowering medication, and 96% used 
antithrombotic medication. Median intake of EPA-DHA was 89.2 (IQR: 36.3-158.6) 
mg/d. The median daily fish intake was 10.6 (IQR: 3.6, 17.4) g and 30% of all patients 
had a fish intake below 5g/d. Baseline characteristics of the study population by n-3 
treatment groups are shown in Table 1. Baseline characteristics including FGF23 were 






Table 1. Baseline characteristics of 352 patients of the Alpha Omega Trial with cystatine C based eGFR<60 ml/min by 
treatment groups 






 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Age (yrs) 73.0 ± 5.0 72.9 ± 4.8 73.1 ± 5.1 72.8 ± 4.7 
Body mass index (kg/m2) 28.3 ± 4.5 27.8 ± 4.2 28.4 ± 4.0 28.0 ± 4.2 
Time since MI  (yrs)a 4.0  (2.0, 6.3) 3.4 (1.7, 5.5)  4.6 (2.2, 6.9)  3.6 (1.7, 5.7) 
Systolic BP (mmHg) 143.0 ± 25.8 141.3 ± 23.8 147.9 ± 20.2 144.8 ± 23.8 
Diastolic BP (mmHg) 78.2 ± 11.4 79.0 ± 11.4 78.5 ± 11.0 79.1 ± 11.6 
Glucose (mmol/L) 6.0 ± 1.6 5.8 ± 1.7 6.4 ± 2.5 6.3 ± 2.0 
Total serum cholesterol 
(mmol/L) 
4.8 ± 1.0 4.8 ± 1.1 5.0 ± 1.1 5.1 ± 0.9 
LDL-cholesterol (mmol/L) 2.7 ± 0.7 2.7 ± 1.0 2.9 ± 0.9 2.9 ± 0.8 
HDL-cholesterol (mmol/L) 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 
Triglycerides (mmol/L) 1.7 (1.3, 2.4) 1.8 (1.4, 2.2) 1.9 (1.4, 2.5) 1.9 (1.5, 2.6) 
Fish intake (g/d)a 10.2 (1.4, 17.2) 9.1 (2.6, 15.9) 10.7 (4.2, 17.6) 14.2 (5.2, 18.7) 
EPA+DHA (mg/d)a 77.0 (33.4, 152.5) 65.4 (25.2, 136.7) 89.2 (39.4, 166.6) 111.8 (51.3, 184.2) 
Serum cystatin C (mg/L) 1.4 ± 0.3 1.4 ± 0.2 1.4 ± 0.3 0.5 ± 0.3 
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eGFR cystatin C based 
(ml/min/1.73m2) 
48.6 ± 10.5 47.8 ± 8.8 49.6 ± 9.9 46.4 ± 10.1 
hsC-reactive protein (mg/l) a 3.4 (1.5, 6.1) 3.3 (1.5, 6.5) 3.2 (1.3, 5.2) 3.0 (1.7, 5.9) 
 % (n) % (n) % (n) % (n) 
Sex (men) 73 (69) 70 (57) 63 (60) 70 (55) 
Ethnicity, white 99 (94) 99 (81) 99 (95) 100 (79) 
Current cigarette smokers  14 (13) 20 (16) 17 (16) 15 (12) 
Alcohol use % (n) 
none 
< 10 g/d 
≥ 10-20 g/d 









































Prevalent diabetes % (n) 25 (24) 23 (19) 32 (31) 25 (20) 
Obesity% (n) 30 (28) 30 (24) 29 (28) 27 (21) 
Use of blood pressure 96 (91) 95 (78) 92 (88) 92 (73) 
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lowering drugs % (n) 
Use of ACE-inhibitor and/or 
Angiotensin blocker % (n) 
64 (61) 52 (43) 67 (64) 60 (47) 
Use of statins % (n) 80 (76) 78 (64) 77 (74) 81 (64) 
Use of anti-thrombotic 
drugs% (n) 
95 (90) 96 (79) 96 (92) 98 (77) 
Physically active % (n) 
No 































Values are given as mean±SD or a median (IQR) for continuous variables, or % (n) for categorical variables. ACE, angiotensin-converting enzyme; 




Intake of n-3 fatty acids 
Ninety-six percent of patients used margarines >80% of the time and the mean 
intake of margarines during the trial was 19.7 (SD 4.0) g/d proving an additional amount 
of 236 mg/d EPA with 158 mg/d DHA, 1.99 g/d ALA or both, in the active treatment 
groups. Fish oil capsules or supplementation were used by 21 (6.0%) patients, with a 
similar distribution over all treatment groups.  
 
Effect of n-3 fatty acids on plasma FGF23 levels 
Patients participated in the trial for a median of 41.3 (IQR: 40.8, 41.9) months. At 
baseline, geometric plasma mean FGF23 levels were 117 (95%CI 110 to 124) RU/ml 
and increased to 150 (140 to 162) RU/ml at follow-up. In parallel, geometric mean 
FGF23 levels increased during follow-up across all groups (Table 2).  
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Table 2. Effect of 40 months intervention of n-3 fatty acids on change in FGF23 levels in patients of the Alpha Omega Trial 
according to study group 
 Pre-treatment 
(95%CI)a 
Post-treatment (95%CI) a Post-treatment 
adjusted for pre-





Placebo (n=79) 120.3 (104.2, 138.9) 150.6 (128.3, 176.9) 147.3 (130.4, 166.3)   
Active treatments      
EPA-DHA (n=82) 120.6 (104.0, 139.8) 142.2 (124.0, 163.1) 138.8 (123.2, 156.3) -6% (-23%, 11%) 0.49 
ALA (n=96) 115.1 (103.6, 127.9) 152.8 (131.9, 177.1) 154.3 (138.3, 172.3) +5% (-12%, 21%) 0.57 
EPA-DHA plus ALA (n=95) 112.0 (100.8, 124.4) 154.8 (134.3, 178.4) 159.5 (142.7, 178.1) +8% (-9%, 24%) 0.34 
n-3 fatty acids group combined (n=273) 115.6 (108.1, 123.7) 150.2 (138.4, 163.0) 151.2 (141.6, 161.4) -3% (-16%, 11%) 0.71 
ALA vs. Placebo or EPA-DHA only (n=191 vs. 161)d 113.5 (105.5, 122.2) 153.8 (139.0, 170.2) 156.9 (145.1, 169.6) -9% (-21%, 2%) 0.11 
EPA-DHA vs placebo or ALA only (n=177 vs. 175)d 115.9 (106.1, 126.6) 148.8 (134.9, 164.2) 149.5 (137.9, 162.2) +1% (-11%, 13%) 0.86 
a Values are back-transformed geometric means (95% confidence interval of the mean), obtained by analysis of covariance (ANCOVA); b % effect of active treatment compared with 
placebo with 95% CI; c p-Values compared with placebo obtained by ANCOVA; d According to the 2x2 factorial design the two groups that received ALA were combined and compared 
with the two groups that did not receive ALA. Similarly, the two groups that received EPA-DHA were combined and compared with the two groups that did not receive EPA-DHA; ALA: 
alpha-linoleic acid; DHA: docosahexaenoic acid; EPA: eicopentaenoic acid; FGF23: fibroblast growth factor. 
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Achieved FGF23 levels, adjusted for baseline FGF23 levels, were similar across 
treatment groups.  Relative changes in FGF23 were close to zero and not statistically 
significant (all P>0.3) in the comparisons for EPA-DHA, ALA, EPA-DHA + ALA vs. 
placebo. The change in plasma FGF23 levels over time was inversely correlated with 
the change in eGFR over 40 months (spearman correlation coefficient=-0.43, 
p<0.0001). During follow-up, eGFR decreased from 48.2 (SD 9.9) to 46.1 (14.5) 
ml/min/1.73 m2.  
Secondary analyses using the 2x2 factorial design approach (two way ANOVA) 
comparing EPA-DHA vs placebo/ALA and ALA vs EPA-DHA/placebo showed similar 
results (Table 2). Analyses by subgroups (prevalent diabetes, obesity or a combination 
of the two conditions) also demonstrated no effects of any of the types of n-3 fatty acid 
supplementation on plasma FGF23 levels over a 40-month period (data not shown). 
The results were similar when patients with extreme FGF23 values (>600 RU/ml) were 





The main finding of this study is that in myocardial infarction patients with 
impaired renal function (eGFR <60 ml/min/1.73 m2), n-3 fatty acid supplementation did 
not reduce plasma C-terminal FGF23 levels. The rationale for the current study was that 
on the one hand FGF23 has been robustly associated with an increased cardiovascular 
risk in CKD patients, which requires prospective intervention studies targeting plasma 
FGF23, and on the other hand our recent finding that n-3 fatty acid intake is 
independently associated with plasma C-terminal FGF23 levels in renal transplant 
recipients11.  
When we identified n-3 fatty acid intake as an independent determinant of FGF23 
levels in our previous study, we hypothesized that the anti-inflammatory effects of n-3 
fatty acids would influence renal expression of klotho, a major cofactor for the FGF23 
receptor23. Accordingly, several publications have now linked an inflammatory state with 
higher levels of FGF2324-25. In vitro, n-3 fatty acids are able to reduce inflammation in 
tubular epithelial cells26, and also reduce oxidative stress27, another factor regulating 
renal klotho expression in vitro and in vivo28-29. Whether n-3 supplementation at the 
dose used in the Alpha Omega Trial was capable of reducing renal inflammation or 
oxidative stress in this subcohort with impaired renal function is unclear, although a 
secondary analysis of the entire Alpha Omega Trial population demonstrated no effect 
of n-3 fatty acid supplementation on circulating high-sensitivity C-reactive protein, 
reflecting systemic inflammation30. Although several other randomized controlled trials 
used a much higher dose of n-3 fatty acids (1-6 grams/day), most of these studied also 
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did not show a significant effect on circulating parameters of inflammation31-33, although 
this does not exclude an effect on renal inflammation.  
To our knowledge, this is the first study with long-term follow-up to prospectively 
assess the effect of n-3 fatty acids on circulating FGF23 levels. Our findings are in line 
with a previous open label study in 47 hemodialysis patients treated with n-3 fatty acids 
or control treatment for 6 months, in which also no effect was observed on plasma 
FGF23 levels14. Furthermore, our results can be reconciled with recently published data 
from the Alpha Omega Trial12, showing that in patients with impaired renal function at 
baseline, the subsequent decline in renal function was slightly (yet significantly) less 
pronounced in patients on EPA-DHA treatment compared to placebo-treated patients. 
Yet, this small effect is unlikely to have resulted in a detectable change in plasma 
FGF23 levels in our study. Possibly a higher dose of n-3 fatty acids might be able to 
induce a stronger effect on both renal function, plasma FGF23 levels, or both. 
Our study has several strengths and limitations. Strengths include the relatively 
long follow-up (40 months), the centrally analyzed cystatin C and FGF23 
measurements, the good compliance to n-3 fatty acid supplementation, the balanced 
randomization and balanced drop-out rates among the treatment arms, and the n-3 fatty 
acids doses that are comparable to the recommended daily allowance and thus the 
real-life situation. The lack of a dose-response design is a limitation of our study, as is 
the relatively low n-3 fatty acids dose. Moreover, patients were already treated with the 
state-of-the-art post-myocardial infarction medical therapy including statins, 
antihypertensive and antithrombotic medication, which may have diluted the treatment 
effect. Another limitation is that the population of our current study, elderly subjects with 
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cardiovascular history and impaired renal function, differs in several aspects from the 
renal transplant population in which we initially identified the association between n-3 
fatty acid intake and FGF23 levels11, among others in terms of cardiovascular history 
and medication use (particularly immunosuppressive medication), although renal 
function was comparable among both studies. Furthermore, given the prerequisite of a 
history of myocardial infarction, our study cohort is not representative for CKD patients 
in general. Finally, we measured FGF23 in non-fasting blood samples which could have 
influenced the results; although differential associations with outcomes have been 
associated for fasting vs non-fasting serum phosphorus levels, this is unknown for 
FGF23 levels34.  
In conclusion, our data do not support n-3 fatty acid supplementation to reduce 
FGF23 levels in post-myocardial infarction patients with impaired renal function. 
Whether n-3 fatty acids, particularly when given in a higher dose, may affect FGF23 
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Chronic kidney disease (CKD) is relatively common, affecting 10-15% of the 
global population, and devours a considerable proportion of health care budgets 
worldwide. Although the development of pharmacological agents targeting the renin-
angiotensin-aldosterone system in the 80s en 90s of the previous century have resulted 
in the possibility to delay CKD progression, this delay comes down to just a modest 
postponement of end-stage renal disease and its cardiovascular complications, i.e a 
postponement of approximately 4 months (Figure 1) as compared to regular 
antihypertensive treatment. This applies to ACE inhibitor and ARB alike.     
 
Figure 1. Cumulative proportion of patients reaching end-stage renal disease in the IDNT trial. Treatment 
with irbesartan delayed the progression towards end-stage renal disease by approximately 4 months 
compared with the placebo or amlodipine groups, for example from 36 to 40 months of follow-up, as 




Disappointingly, since the introduction of ACE inhibitors and ARBs for renoprotection 
in the 1990’s, no other therapy has convincingly been able to further retard 
progression of CKD. Similarly, no effective specific therapies to prevent the excess of 
cardiovascular disease have been identified in CKD patients. Considering the 
excessively high cardiovascular risk in renal patients, in particular in patients end 









Figure 2. Cardiovascular mortality defined by death due to arrhythmias, cardiomyopathy, cardiac arrest, 
myocardial infarction, atherosclerotic heart disease, and pulmonary edema in the general population 
compared with dialysis patients and renal transplant recipients (USRDS data). Data are stratified by age, 
race, and sex. Reproduced from RN Foley et al2. 
 
Increasing evidence indicates that not only conventional cardiovascular risk 
factors, like hypertension, smoking and high cholesterol are involved in the excess 
cardiovascular risk in renal patients, but that risk factors specific to renal disease are 
important as well. Among these risk factors, deregulations of phosphate metabolism 
stand out as important candidate-pathways for the increased cardiovascular risk in 
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CKD.  Specifically, deregulations in serum phosphate and the phosphaturic hormone 
fibroblast growth factor 23 (FGF23) have strongly been linked with a higher 
cardiovascular risk, and may be specific targets for intervention in CKD and after kidney 
transplantation. An important question is whether (partial) improvement of phosphate 
metabolism after kidney transplantation is responsible for the reduced cardiovascular 
mortality risk compared with the dialysis population and whether a further improvement 
in phosphate metabolism may increase cardiovascular prognosis. Although drugs and 
dietary strategies to target hyperphosphatemia are available, it is still unknown how to 
specifically target FGF23, and whether these strategies may actually improve patient 
morbidity and mortality.  
In chapter 2, we reviewed the literature on phosphate homeostasis, focusing on 
the clinical implications of its deregulation after renal transplantation. Early after 
transplantation, serum phosphate levels decline rapidly in response to restored renal 
function in the context of residually high FGF23 and PTH levels. This may result in deep 
hypophosphatemia requiring phosphate supplementation. In contrast, later after 
transplantation, when renal function has declined, patients may require phosphate-
lowering therapy to normalize serum phosphate, and possible also FGF23 levels. 
Pharmacological and dietary therapies aiming to improve phosphate metabolism are 
available to renal transplant recipients, yet levels of phosphate and, mostly, FGF23 may 
still increase strongly with declining graft function as in CKD. Analogous to the pre-
transplant CKD setting, it seems prudent to aim for normalization of serum phosphate 
and FGF23 levels in renal transplant recipients, although hard endpoint data confirming 
the clinical relevance of reaching these targets in the transplant population are lacking.  
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In chapter 3, we investigated fibroblast growth factor 23 (FGF23) as a potential 
predictor of cardiovascular mortality in a large cohort of kidney transplant recipients. 
Several studies had previously linked a high FGF23 level with adverse cardiovascular 
outcomes in pre-transplant CKD patients. In this study we found strong associations 
between FGF23 and cardiovascular markers, such as NT-proBNP, MR-proANP and 
copeptin. We evaluated the association of FGF23 levels with outcomes in Cox 
regression models, adjusted for several potential confounders, and found that FGF23 
levels were strongly and consistently associated with a higher risk of both 
cardiovascular and all-cause mortality, both independent of renal function. The 
association of FGF23 with graft failure was lost after adjustment for renal function.  
The potential role for a high FGF23 level as an independent predictor of 
cardiovascular outcomes observed in chapter 3 underlines the need for novel 
interventions lowering FGF23 in renal transplant recipients. Although classical 
strategies including a phosphate-restricted diet and phosphate binders are at least 
partly successful to lower phosphate and FGF23 levels, as reviewed in chapter 2, 
additional strategies are required. To design and prioritize anti-FGF23 strategies, it 
would be useful, therefore, to first have an overview of the determinants of FGF23 in the 
clinical setting, including clinical characteristics as well as dietary factors. Moreover, 
given the strong associations observed between parameters of inflammation and 
deregulations in FGF23, it would be interesting to include in such an analysis nutrients 
that, by anti-inflammatory effects have been implicated to have cardioprotective 
properties, such as N-3 polyunsaturated fatty acids (N-3 PUFAs) 3-4.  
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In chapter 4, we analysed the clinical and dietary determinants of FGF23 in a 
cross-sectional study in  stable kidney transplants, including assessment of the possible 
association of  intake of fish (as a dietary source of PUFAs) and the N-3 PUFAs 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with serum FGF23 
levels. This cross-sectional analysis revealed that, indeed, higher intake of fish and 
dietary N-3 PUFAs (EPA-DHA) were associated with lower levels of circulating FGF23, 
independent of potential confounders. Interestingly, in patients with a reduced graft 
function (eGFR the renal function <60 mL/min/1.73 m2) the association between FGF23 
levels and N-3 PUFAs was most pronounced. Based on the findings from this 
observational study, we subsequently performed a prospective study in an animal 
model of CKD.  
In chapter 5, we investigated the effect of N-3 PUFAs supplementation in a 
mouse model of renal inflammation. After inducing inflammation by adenine-enriched 
chow administration, we observed the development of intra-renal inflammation (higher 
levels of renal HMOX, IL-6 and TGF-β expression), accompanied by reduced renal 
expression of klotho (an essential co-factor for the specific receptor for FGF23) and 
renal fibrosis. Conversely, when animals were treated with fish oil-enriched chow (rich in 
N-3 PUFAs), the intra-renal inflammation as well as renal klotho expression and 
collagen deposition were restored to control levels, suggesting that the N-3 PUFAs 
supplementation had strong beneficial effects on renal klotho expression, and prevented 
renal inflammation and fibrosis. These positive and exciting results, and the known 
inverse relationship between renal klotho and FGF23 levels suggest that by restoring 
renal klotho expression, PUFAs may also beneficially impact on circulating FGF23 
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levels. To address this in patients, we measured FGF23 levels in a posthoc analysis of 
the Alpha Omega trial participants with impaired renal function (eGFR <60 ml/min/1.73 
m2). As reported in chapter 6, we found no effects of PUFA supplementation on FGF23 
in this population. Although PUFA supplementation provided a small protective effect on 
renal function in a previous study, this did not translate into a lower FGF23 level in the 
current sub-cohort of the Alpha Omega trial5. However, the PUFA dose was relatively 




Given the strong and consistent association of high plasma FGF23 level with an 
increased risk of cardiovascular mortality, we can conclude that FGF23 should be 
considered a promising candidate-target to improve cardiovascular outcome in renal 
transplant recipients and the CKD population. The observation that N-3 PUFA and fish 
intake was inversely associated with FGF23 levels in renal transplant recipients 
(chapter 4), and the capacity of fish oil supplementation to reduce renal damage in our 
animal study (chapter 5) call for further clinical studies addressing the potential 
cardiorenal protective effects of PUFA-based dietary interventions in CKD and 
transplant patients. The transplant population may be of particular interest, given the 
protective effect of fish-oil aginst rejection, as reported in the 1990’s.  
Although we could not demonstrate an effect of PUFA supplementation on 
FGF23 levels in post-myocardial infarction CKD patients in the Alpha Omega Trial, it is 
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important to note that the supplementation doses of EPA-DHA in this study were 
relatively low, and may therefore have not been sufficient to result in detectable 
reduction of FGF23 levels. Therefore, further intervention studies using higher doses of 
EPA-DHA are needed to confirm the present data. 
Management of phosphate levels has a long tradition in nephrology, and involves 
both dietary phosphate restriction and intestinal phosphate binders6. Yet, few data are 
available on the effect of phosphate correction on FGF23 levels, in CKD patients and 
kidney transplant recipients. However, as patients with hyperphosphatemia have higher 
phosphate intake than patients with hypophosphatemia, so dietary phosphate restriction 
could be useful to avoid or correct high phosphate levels and hence  prevent increases 
in FGF23 levels7. To this purpose, special attention on inorganic phosphate intake, 
commonly added as preservative in processed foods, should be paid since its intestinal 
absorption is much higher than organic phosphate and could exert a bigger impact on 
phosphate and FGF23 levels8. The conventional phosphate binders includes, mainly, 
sevelamer and calcium salts6. Some pharmacological novelties have been studied and 
are still under (pre-) clinical investigation. Nicotinamide, an inhibitor of intestinal NaPi-2b 
transporters has presented positive results on decreasing phosphate levels in CKD 
patients9-10. In line, tenapanor, an inhibitor of the intestinal sodium-hydrogen exchanger 
3, has also shown to decrease phosphate uptake as well as ectopic calcification in an 
experimental model of CKD11. Although such drugs are still not established therapies to 
decrease phosphate levels, in the future, nicotinamide and tenapanor may contribute to 
the management of deregulated phosphate homeostasis in both CKD and transplant 
patients. Recently, an experimental study used a monoclonal FGF23 antibody to 
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evaluate the impact of chronic FGF23 neutralization on CKD-MBD. However, the 
neutralization of FGF23 increased serum phosphate levels and contributed to increase 
mortality in that CKD-MBD rat model12. 
Although much more is known about phosphate/FGF23 metabolism, there are 
two important questions to be answered:  Firstly, what is the best approach to improve 
phosphate metabolism in both CKD and renal transplantation? Secondly, would 
normalization of phosphate metabolism reduce cardiovascular morbidity and mortality, 
and contribute to long-term preservation of renal function, in CKD and after kidney 
transplantation? The answers to these questions will provide a basis for further 
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 A doença renal crônica (DRC) é relativamente comum, afeta cerca de 10-15% da 
população mundial e devora uma porção considerável do orçamento de saúde no 
mundo inteiro. Embora o desenvolvimento de agentes farmacológicos direcionados ao 
sistema renina-angiotensina-aldosterona, nos anos 80 e 90 do século passado, tenha 
resultado na possibilidade de retardar a progressão da DRC, este retardo é modesto no 
que se refere à evolução até a doença renal em estágio terminal e suas complicações 
cardiovasculares. 
 Infelizmente, desde a introdução de inibidores da ECA e BRAs destinados à 
renoproteção nos anos 90, nenhuma outra terapia foi capaz de retardar a progressão 
da DRC. Do mesmo modo, nenhuma terapia específica no sentido de prevenir o 
excesso de doença cardiovascular tem sido identificada para pacientes com DRC. 
Considerando o elevado risco de doença cardiovascular em pacientes renais, em 
particular pacientes em estágio final de doença renal, este é ainda o maior desafio. 
 Novas evidências indicam que, não somente fatores de risco cardiovascular 
convencionais como hipertensão, fumo e elevados níveis de colesterol estejam 
envolvidos no elevado risco cardiovascular em pacientes renais, mas que fatores 
específicos da doença renal estejam, também, envolvidos. Dentre esses fatores de 
riscos, distúrbios do metabolismo de fósforo e do hormônio fosfatúrico, fator de 
crescimento fibroblastico 23 (FGF23) tenham uma forte ligação com riscos mais 
elevados de desenvolvimento de doença cardiovascular e podem ser alvos específicos 
de intervenção em pacientes com DRC e após o transplante renal. Uma questão 
importante é se uma melhora (parcial) do metabolismo de fósforo após o transplante 
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renal é responsável pelo reduzido risco de mortalidade cardiovascular comparado com 
a população em diálise e ainda se a melhora do metabolismo de fósforo pode aumentar 
o prognóstico cardiovascular. Embora medicamentos e estratégias dietéticas 
direcionadas a hiperfosfatemia estejam disponíveis, ainda é desconhecido como 
abordar especificamente o FGF23, e se essas estratégias podem, de fato, melhorar a 
morbidade e mortalidade dos pacientes. 
 No capítulo 2, nós fizemos uma revisão da literatura sobre homeostase de 
fósforo, focando nas implicações clínicas da sua desregulação após o transplante 
renal. No pós-transplate imediato, os níveis séricos de fósforo reduzem rapidamente 
em resposta à recuperação da função renal no contexto de elevados níveis (residuais) 
de FGF23 e PTH. Isto pode resultar em importante hipofosfatemia e requerer 
suplementação de fósforo. Por outro lado, no pós-transplante tardio, quando a função 
renal está reduzida, os pacientes podem precisar de terapias para reduzir ou 
normalizar o fósforo sérico e possivelmente FGF23. Terapias farmacológicas e 
dietéticas objetivando melhorar o metabolismo de fósforo estão disponíveis para 
pacientes transplantados renais, e ainda os níveis de fósforo e, principalmente, FGF23 
podem ainda aumentar fortemente com a redução da função renal como na DRC. Da 
mesma forma que em pré-transplantados com DRC, parece prudente  objetivar a 
normalização do fósforo e FGF3 séricos em transplantados renais, embora fortes 
resultados confirmando a relevância clínica de alcançar esses objetivos ainda são 
insuficientes. 
 No capítulo 3, nós investigamos o fator de crescimento fibroblástico 23 (FGF23) 
como um potencial preditor de mortalidade cardiovascular em uma coorte de 
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receptores de transplante renal. Vários estudos mostraram, previamente, uma relação 
entre elevados níveis de FGF23 com resultados cardiovasculares adversos em 
pacientes pré-transplante com DRC. Neste estudo, nós encontramos fortes 
associações entre marcadores cardiovasculares, como NT-proBNP, MR-proANP e 
copeptina. Nós avaliamos a associaçãodos níveis de FGF23 com resultados clínicos 
usando modelos de regressão de Cox, ajustados por vários confundidores e 
encontramos que os níveis de FGF23 foram fortemente e consistentemente associados 
com um elevado risco de mortalidade cardiovascular e por todas as causas, 
independentemente da função renal. 
 O potencial papel de elevados níveis de FGF23 como um preditor independente 
de desfechos cardiovasculares observados no capítulo 3 esconde a necessidade de 
novas invenções direcionadas à redução do FGF23 em receptores de transplante renal. 
Embora as estratégias clássicas incluindo restrição dietética de fósforo e quelantes de 
fósforo são pelo menos parcialmente bem suscedidos em reduzir os níveis de fósforo e 
FGF23, como revisado no capítulo 2, estratégias adicionais são necessárias.Para 
definir estratégias anti-FGF23, seria útil, portanto, primeiro ter uma visão geral dos 
determinantes do FGF23 no cenário clínico, incluindo as características clínicas e 
fatores dietéticos. Além disso, dada a forte associação observada entre parâmetros de 
inflamação e distúrbios no FGF23, seria interessante incluir, então, uma análise de 
nutrientes que, através de efeitos anti-inflamatórios que tenham sido implicados em 
desfechos cardiovasculares, tal como ácido-graxo N-3. 
 No capítulo 4, nós analisamos os determinantes clínicos e dietéticos do FGF23 
em transplantados renais estáveis, avaliando inclusive, a possível associação de 
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ingestão de peixe (como uma fonte dietética de PUFAs) e o N-3 EPA e DHA, com 
FGF23. Este estudo revelou que, de fato, maior ingestão de peixe e N-3 dietético 
(EPA/EPA) foram associados com menores níveis de FGF23 circulante, independente 
de potenciais fatores confundidores. Interessantemente, em pacientes com função 
renal diminuída (função renal <60 mL/min/1.73 m2) a associação entre níveis de FGF23 
e N-3 PUFAs foi mais pronunciada. Baseados nos achados deste estudo 
observacional, nós desenhamos um estudo prospectivo em um modelo animal de DRC. 
No capítulo 5, nós investigamos o efeito da suplementação de N-3 PUFAs em um 
modelo animal de inflamação renal. Após induzir inflamação através da administração 
de uma dieta enriquecida de adenina, nós observamos o desenvolvimento de 
inflamação intra-renal, acompanhada por uma redução da expressão renal de klotho 
(um co-receptor essencial para o receptor específico para o FGF23) e fibrose renal. Por 
outro lado, quando os animais foram tratados com uma dieta enriquecida com óleo de 
peixe (rica em N-3 PUFAs), a inflamação intra-renal bem como a expressão renal de 
klotho e deposição de colágeno foram restauradas a níveis observados nos animais do 
grupo controle, sugerindo que a suplementação de N-3 PUFAs promoveu efeitos 
benéficos na expressão renal de klotho e preveniu inflamação renal e fibrose. Tais 
resultados e a conhecida relação inversa entre expressão renal de klotho e níveis de 
FGF23 sugerem que, através da restauração da expressão de klotho, PUFAs podem 
também exercer um efeito benéfico nos níveis de FGF23 circulantes. Para avaliar 
esses efeitos em pacientes, nó medimos os níveis de FGF23 em participantes do 
estudo Alpha Omega Trial com déficit de função renal (eGFR <60 ml/min/1.73 m2). 
Como mencionado no capítulo 6, nós não observamos efeito da suplementação de 
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PUFA nos níveis de FGF23 nesta população. Embora a suplementação de PUFA tenha 
promovido um discreto efeito protetor na função renal em um estudo prévio, isto não 
promoveu uma redução dos níveis de FGF23 no estudo Alpha Omega Trial. Entretando 
a dose de PUFA administrada foi relativamente baixa e devido ao desenho post-hoc , a 















Chronische nierziekten komen relatief vaak voor, bij zo’n 10-15% van de 
wereldpopulatie, en dit ziektebeeld maakt aanspraak op een aanzienlijk deel van de 
gezondheidszorg budgetten wereldwijd. Ondanks de ontwikkeling in de jaren 80 en 90 
van farmacologische middelen welke het renine-angiotensine-aldosteron systeem 
targetten en heeft geleid tot de mogelijkheid om de CKD progressie te vertragen, blijkt 
deze vertraging uiteindelijk slechts een bescheiden uitstel van eind stadium nierfalen en 
zijn cardiovasculaire complicaties.  
Helaas, is er, sinds de introductie in de jaren 90 van de ACE-remmers en 
angiotensine-renine-blokkers (ARB’s) voor renoprotecti, nog geen andere therapie in 
staat geweest om de progressie van CKD verder te vertragen. Daarnaast zijn er geen 
specifieke therapieën gevonden om het vaker voorkomen van cardiovasculaire ziekten 
te voorkomen bij CKD patiënten. 
Hierbij het excessief hoge cardiovasculaire risico in ogenschouw nemend, in het 
bijzonder voor patiënten met eind stadium nierfalen, blijft dit een enorme uitdaging.  
Er komt steeds meer bewijs voor de hypothese dat niet alleen conventionele 
cardiovasculaire risicofactoren, zoals hypertensie, roken en een hoog cholesterol, 
betrokken zijn bij het verhoogde cardiovasculaire risico voor nier patiënten, maar dat 
risicofactoren welke specifiek zijn voor nierziekten, ook belangrijk zijn. Onder deze 
risicofactoren blijkt deregulatie van het fosfaat metabolisme in het bijzonder belangrijk te 
zijn als mogelijke route voor het verhoogde cardiovasculaire risico in CKD. In het 
bijzonder de deregulatie van het serum fosfaat en het fosfaturisch hormoon fibroblast 
groeifactor 23 (FGF23) blijken sterk gecorreleerd aan een verhoogd cardiovasculair 
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risico, en kunnen mogelijk specifieke doelen zijn voor interventie voor CKD en na 
niertransplantatie. Een belangrijke vraag is of de (gedeeltelijke) verbetering van het 
fosfaat metabolisme na niertransplantatie verantwoordelijk is voor het verlaagde 
cardiovasculaire mortaliteitsrisico in vergelijking met de dialyse populatie, en of een 
verdere verbetering in het fosfaatmetabolisme de cardiovasculaire prognose kan 
verbeteren. Ondanks het feit dat er medicijnen en dieetadviezen beschikbaar zijn om 
hyperfosfatemie te targetten, is het nog steeds niet bekend hoe men FGF23 specifiek 
kan blokkeren, en of deze strategieën daadwerkelijk de morbiditeit en mortaliteit van de 
patiënt verbeteren.  
In hoofdstuk 2, hebben wij literatuur gereviewd over de fosfaat homeostase, 
toegespitst op de klinische implicaties van deze deregulatie na niertransplantatie. Vroeg 
na de transplantatie, dalen de serum fosfaat levels snel als reactie op de herstelde 
nierfunctie in de context van een residu hoog FGF23 en PTH levels. Dit kan als gevolg 
leiden tot diepe hypofosfatemie, waarbij fosfaat supplementatie nodig is. 
Tegenovergesteld, kunnen patiënten laat na transplantatie, wanneer de nierfunctie 
afgenomen is, fosfaat-verlagende therapie nodig hebben om hun serum fosfaat te 
normaliseren, en mogelijk ook de FGF23 levels. Farmacologische en dieet-gerichte 
therapieën welke als doel hebben om het fosfaat metabolisme te verbeteren zijn 
beschikbaar voor de ontvangers na niertranplantatie. Echter de levels van fosfaat en, 
meestal FGF23, kunnen net als in CKD nog steeds sterk toenemen met als gevolg 
afname van de functie van het donororgaan.  
Analoog aan de pre-transplantatie CKD-setting, lijkt het logisch om een 
normalisatie van het serum fosfaat en de FGF23 na te streven in ontvangers van 
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niertransplantatie, ook al ontbreken de harde eindpunt data om de klinische relevantie 
van het behalen van deze doelen in de transplantatie populatie te bevestigen.  
In hoofdstuk 4, hebben wij fibroblast groeifactor 23 (FGF23) onderzocht als een 
potentiële voorspeller van cardiovasculaire mortaliteit in een groot cohort van 
ontvangers in niertransplantatie. Verscheidene studies hebben eerder een hoog FGF23 
level gelinked met nadelige cardiovasculaire uikomsten in pre-transplantatie CKD 
patiënten. In deze studie hebben wij sterke associaties gevonden tussen FGF 23 en 
cardiovasculaire markers, zoals NT-proBNP, MR-proANP en copeptine. We hebben de 
associatie tussen FGF23 levels en uitkomsten geëvalueerd met een Cox regressie 
model, aangepast voor verscheidene mogelijke confounders, en we hebben gevonden 
dat FGF23 levels sterk en consistent geassocieerd zijn met een hoger risico op zowel 
de cardiovasculaire als de algemene mortaliteit, beide onafhankelijk van de nierfunctie. 
De associatie van FGF23 met het falen van het donororgaan bestond niet meer na 
correctie voor nierfunctie.  
De potentiële rol voor een hoof FGF23 level als een onafhankelijke voorspeller 
van cardiovasculaire uikomsten zoals waargenomen in hoofdstuk 3 onderschrijft de 
behoefte voor nieuwe interventies, waarbij het FGF23 verlaagd wordt in ontvangers van 
een donornier. Ook al zijn klassieke strategieën zoals een fosfaat-beperkt diet en 
fosfaatbinders op zijn minst deels succesvol in het verlagen van het fosfaat en het 
FGF23, zoals besproken in hoofdstuk 2,  blijft er behoefte aan aanvullende strategieën. 
Om anti-FGF23 strategieën te ontwikkelen en te prioriteren, is het belangrijk om eerst 
een overzicht te verkrijgen over de determinanten van FGF23 in de kliniek, inclusief 
klinische karakteristieken en dieetfactoren. Daarnaast zou het, gezien de sterke 
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associaties tussen inflammatieparameters en FGF23 deregulatie, interessant zijn om in 
deze analyse voedingsstoffen te bekijken, waarvan wegens anti-inflammatoire effecten 
gedacht wordt dat zij cardioprotectieve eigensschappen hebben, zoals N-3 
polyunsaturated fatty acids (N-3 PUFAs).  
In hoofdstuk 4, hebben we de klinische- en voedingsdeterminanten van FGF23 
geanalyseerd in een cross-sectionele studie in stabiele niertransplantaten, inclusief het 
bepalen van de mogelijke associatie van het eten van vis (als een voedingsbron van 
PUFAs), de N-3 PUFAs eicosapentaenoic acid (EPA) en docosahexaenoic acid (DHA), 
met serum FGF23 levels. Deze cross-sectionele analyse bevestigde dat een hogere 
intake van vis en N-3 PUFAs (EPA-DHA) in het dieet, inderdaad zijn geassocieerd met 
lagere levels van circulerend FGF23, onafhankelijk van mogelijke confounders. 
Interessant genoeg, blijkt, in patiënten met een verminderde donor nierfunctie (eGFR de 
nierfunctie <60 mL/min/1.73 m2), de associatie tussen FGF23 levels en N-3 PUFAs het 
meest uitgesproken. Op basis van de bevindingen in deze observationele studie, 
hebben we vervolgens een prospectieve studie uitgevoerd in een diermodel voor CKD.  
In hoofdstuk 5, hebben we het effect van N-3 PUFAs supplementatie 
onderzocht in een muismodel voor inflammatie in de nier. Na het induceren van de 
inflammatie door adenine-verrijkte muizenvoeding, hebben we de ontwikkeling van 
intra-renale inflammatie (verhoogde levels van renale HMOX< IL-6 en TGF- β 
expressive) geobserveerd, gepaard gaand met de verminderde renale expressive van 
klotho (een essentiële co-factor voor de specifieke receptor voor FGF23) en renale 
fibrose. Tegengesteld; Wanneer dieren behandeld werden met visolie verrijkte voeding 
(rijk aan N-3 PUFAs), herstelden zowel de intra-renale inflammatie als de renale klotho 
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expressie  en de collageen depositie zich ten opzichte van de controle levels, wat 
suggereert dat de supplementatie van N-3 PUFAs een sterk voordelige effecten had op 
renale klotho expressie, en renale inflammatie en fibrose voorkwam. Deze positieve en 
spannende resultaten, en de bekende tegengestelde relatie tussen renal klotho en 
FGF23 levels suggereren dat door middel van het herstellen van de renale klotho 
expressive, PUFAs mogelijk ook een voordelig effect kunnen hebben op circulerende 
FGF23 levels. Om dit te onderzoeken in patiënten, hebben wij FGF23 levels gemeten in 
een posthoc analyse van de patiënten in de Alpha Omega trial met een verslechterde 
nierfunctie (eGFR <60 ml/min/1.73 m2). Zoals vermeld in hoofdstuk 6,  vonden we 
geen effecten van PUFA supplementatie op FGF23 in deze populatie. Ondanks dat 
PUFA supplementatie een klein beschermend effect op de nierfunctie liet zien in een 
eerdere studie, werd dit niet vertaald in een lager FGF23 in dit huidige sub-cohort van 
de Alpha Omega trial. Echter, de PUFA dosering was relatief laag, en wegens het post-
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